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Osteoporosis, an age-related bone disease characterized by low bone mass, is a 
potential public health problem responsible for over 8.9 million fractures annually. 
From an engineering perspective to understanding the mechanism of increased 
fragility with osteoporosis, we applied engineering theory to study this complex 
composite material, bone. Amount of bone, bone distribution, and tissue material 
properties are determinants of whole bone strength. Parathyroid hormone (PTH, 
teriparatide, hPTH [1-34]) is a FDA-approved anabolic osteoporosis treatment. PTH 
has shown to reduce fracture risk by over 50% and increased bone volume fraction. 
However, the alterations in material properties and mechanical properties with PTH 
treatment, and the correlations to bone mechanical failure are unknown. The 
objectives of this research were to 1) examine alterations in microstructure and tissue 
properties of both cortical and cancellous bone with PTH treatment using an 
osteopenia sheep model, and 2) investigate the influence of microstructure and 
anisotropic material properties on crack propagation in a pre-notched cortical beam 
under bending.  
 To investigate the alterations in tissue properties across different length scales, 
 a large, multi-level experiment was designed for both cortical and cancellous bone in 
an osteopenia sheep model. The first study focused on cortical bone and the effect of 
PTH treatment was greater at the micro- and nanoscale than at the whole bone level. 
There was no difference with whole-bone strength; however, fatigue life has shown to 
increase compared to other bisphosphonate-treated samples whereas fracture 
toughness was decreased in PTH-treated group and osteon density was higher. 
Furthermore, mineralization increased whereas indentation modulus decreased and 
hardness reduced with PTH treatment. Millimeter and nano-scale material properties 
were correlated with whole bone strength, but fatigue properties correlated little to 
bending strength or fracture toughness.  
In the second study, cancellous bone was examined. There was no difference 
in monotonic compressive strength with PTH treatment; however, PTH-treated group 
preserved mechanical properties during cyclic loading compared to vehicle group. 
Additionally, PTH increased the volume fraction of rod-type trabeculae and decreased 
mineralization whereas nanoindentaion and hardness were not different. Correlating 
tissue composition, microstructure, and mechanical performance, energy dissipation 
was highly correlated with volume fraction of rods and mineralization.  
 In the third study, fracture behavior in a single pre-notched cortical bone tissue 
was examined with finite element based simulation software (FRANC2D). The role of 
anisotropy of fracture toughness and of altered microstructure in crack trajectory and 
the force needed to propagate a crack was investigated. Cortical bone with more 
osteons located further away from the applied loads to maximize intact material would 
withstand more load before propagating cracks and fracturing. 
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CHAPTER 1 
INTRODUCTION* 
 
Musculoskeletal tissues such as bone play critical roles in bearing the loads created 
during activities of daily living. As a result, mechanical properties of bone are critical 
to its function and relevant to clinical conditions. Understanding the basic composition 
and architecture of bone tissue provides a base from which to understand tissue 
function and mechanical behavior. Diseases and other pathologic conditions often alter 
the mechanical properties of bone tissue resulting in disruptions of normal function. 
To be successful, treatments must restore/maintain the mechanical function.  
 
1.1   Bone Composition and Architecture 
 
Bone is the most abundant of the musculoskeletal tissues. Bone tissue contains 40% 
inorganic mineral, 35% organic matrix, and 25% water by weight. The inorganic 
phase is made of a ceramic crystalline type of mineral called hydroxyapatite. The 
organic phase is composed primarily of type I collagen, along with minor collagen 
types and noncollagenous proteins. When loaded, the mineral contributes to 
compressive behavior, and the collagen contributes to tensile behavior. Additionally, 
bone is a hierarchical material (Figure 1.1). At the lowest level (approximately 0.1 
µm scale), bone consists of mineralized collagen fibrils embedded within the organic 
extracellular matrix. These fibrils are arranged into lamellae (7 to 10 µm thick). 
Circumferential structures of multiple lamellae with a central Haversian canal form 
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structures known as osteons (approximately 200 µm in diameter). Lamellae and 
osteons are arranged into cortical or cancellous bone tissue at the highest level of 
scale, greater than 1 mm. Cortical bone consists of densely packed and longitudinally 
oriented osteons and lamellae. Cancellous bone, also known as trabecular bone, is an 
open cellular structure with a spatially variable microstructure consisting of individual 
struts or trabeculae. 
 
 
Figure 1.1 Hierarchical structure of bone from macro- to nano-scale. Image adapted  
                  from Rho et al.(1). 
 
Bone tissue can change its microstructure and composition actively through the 
tissue’s ability to repair damage and adapt to its mechanical environment by 
coordinated cellular activity known as modeling or remodeling. Modeling occurs 
primarily during growth and involves net bone formation and shaping through bone 
formation by osteoblasts and/or resorption by osteoclasts. Remodeling replaces old or 
damaged bone tissue and creates new tissue. In contrast to modeling, remodeling is 
performed by the coupled action of the osteoclast and osteoblast cells in bone. 
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Osteoclasts and osteoblasts are the key actors in bone remodeling; osteocytes are 
believed to be the sensors. Ideally, the amount of new bone formed is equal to the 
volume of older tissue removed. With age, however, this process becomes less 
efficient, and bone loss outpaces new bone formation, leading to reduced bone 
strength. This progressive bone loss leads to the development of osteoporosis and can 
be counteracted through the suppression of remodeling, particularly in cases of high 
bone turnover. High turnover rates increase cortical porosity and weaken cancellous 
bone through the loss of connectivity between trabecular plates and struts.(2) Various 
musculoskeletal diseases differentially affect tissue composition and turnover and 
thus, mechanical properties (Table 1.1). 
 
Table 1.1 Tissue Alterations Induced by Musculoskeletal Diseases and Effects on  
                 Mechanical Properties of Bone Tissue  
 
Tissue Alteration Clinical Condition Modulus Ultimate Stress Toughness 
No or low turnover Osteoporosis, 
atypical femoral 
fracture, irradiated 
bone, 
pycnodysostosis 
 
  
High turnover Postmenopausal 
osteoporosis(3) 
 
 
 
Poor collagen Marfan syndrome, 
scurvy, osteogenesis 
imperfecta, Ehlers 
Danlos syndrome 
  
 
 
Poor mineralization Osteomalacia, 
hypophosphatasia, 
hypophosphatemic 
rickets, renal 
osteodystrophy 
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In addition to variations in apparent level properties, spatial variations in tissue 
properties are important because these local changes are evident in the behavior of 
cracks initiation and propagation(4,5). Osteons are layered concentric ring-like 
structures within cortical bone. Osteonal tissue is less mineralized and less stiff 
compared to interstitial matrix, which is primary bone tissue and has been present 
longer than osteonal tissue(6). Through remodeling, tissue age, different from the age 
of animal, within single osteon increases from the center of the osteon towards the 
periphery(7). In cortical bone in primates, material properties and nanomechanical 
properties vary due to tissue age in the osteon(8,9). In the cancellous bone, tissue age 
increases towards the center of each trabecula; therefore, greater treatment effects are 
expected near the surfaces of trabeculae(10,11).  
 
1.2   Bone Quality versus Bone Quantity 
 
Clinically, reduced bone mass are diagnosed by dual-energy x-ray absorptiometry, and 
the reported bone mineral density (BMD) serves as the quantitative evaluation of 
osteoporotic fracture risk. BMD has limitations in predicting fracture risk. Small 
increases in BMD do not correspond with substantial changes in fracture risk in some 
populations such as women without vertebral fractures(12). Factors other than BMD 
that may contribute to fracture risk often are referred to collectively as “bone quality.” 
Therefore, the term bone quality is quite broad and includes bone geometry, 
cancellous morphology, and material properties(13). Some key concepts from 
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biomechanics regarding the determinants of whole bone structural strength are 
required to help define bone quality(1,14). 
 
For bone quality, the structure of interest is the whole bone. In terms of structural 
behavior, different mechanical tests, such as bending, tension, and torsion, can be used 
to determine structural strength and structural stiffness. From these tests, structural 
strength is defined as the failure load of the whole bone, and structural stiffness is 
defined as the ability to resist deformation for a given load(15). These two structural 
measurements are influenced by the geometric distribution of the material and the 
material properties of the tissue(1,14). 
 
Geometry can be determined by a variety of techniques, including noninvasive 
imaging methods such as CT and MRI or destructive sectioning methods. The material 
properties of tissue are more difficult to assess. Tissue composition can be measured 
by chemical methods such as Fourier transform infrared spectroscopy (FTIR) and 
Raman spectroscopy(10). Tissue mineral content also can be obtained from 
microcomputed tomography(16). The mechanical properties of the tissue can be 
measured directly by the mechanical testing of small samples and the indentation of 
small tissue volumes(13). 
 
1.3   Mechanical and Material Properties of Bone at Apparent-Level 
 
Because of this hierarchical microstructure and composition, the material properties of 
bone are anisotropic, varying in different directions, and viscoelastic, depending on 
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the rate of loading. Cortical bone tissue loaded in the longitudinal direction along the 
axis of a long bone is stiffer and stronger than when loaded in the transverse 
direction(17) (Figure 1.2). The stresses experienced by cortical bone during activities of 
daily living such as walking and running are largest in the longitudinal direction. In 
addition to having anisotropic properties in a given loading direction, cortical bone 
strength is greater in compression than in tension (Figure 1.2)(17). The strength and 
stiffness of cortical bone tissue also depend on the loading rate. When the material is 
loaded more quickly, cortical bone behaves more stiffly, but the amount of 
deformation until failure (ultimate strain) decreases(18). In cancellous bone, these 
material properties are difficult to generalize. The material properties depend on the 
apparent density through an exponential relationship(19). Like cortical bone, the 
compressive yield strength of cancellous bone is greater than its tensile yield strength. 
 
A 
 
B 
 
 
 
Figure 1.2 Representative stress-strain curves are shown for bone (A) in tension and  
                  (B) compression. Two curves are shown reflecting different behavior as a  
                  result of specimen orientation relative to the applied load  
                 (longitudinal/transverse).  
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Traditionally, the focus of tissue mechanical behavior has been on whole bone and 
tissue stiffness and failure strength, as described previously. Most in vivo loading 
experienced under normal activity is cyclic; thus, cyclic loading and fatigue behavior 
have gained renewed importance. 
 
Fatigue loading is cyclic with low magnitude loads, the stresses of which are well 
below the ultimate stress required to fracture bone tissue in a single overload (Figure 
1.3). Fatigue loads are created through repetitive activities such as walking and 
running. When a tissue is subjected to fatigue loading, localized damage to the 
structure, such as microcracks, is initiated. With continued cyclic loading, cracks 
accumulate and propagate, reaching critical lengths, and the structure fails. This 
structural fatigue failure also occurs in stress fractures. 
 
 
A 
 
B 
 
Figure 1.3 Graphs show applied cyclic loading and key outcomes for fatigue testing.  
                  Fatigue behavior is determined by applying cyclic loading over time to a  
                  material sample (A) and measuring the number of cycles to failure to  
                  produce peak stress (S) versus the number of cycles to failure (N), resulting  
                  in the representative S-N curves shown for bone and steel (B). Steel  
                 displays an endurance limit, a stress below which failure never occurs,  
                 whereas bone does not have an endurance limit. 
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The fatigue properties of bone have been studied for several decades, and most of this 
work has been performed by examining cortical bone. Fatigue life is influenced by 
loading direction, strain rate, and osteoporosis treatment. Fatigue life of cortical bone 
was longer in compression than in tension(20). Strain rate affects damage accumulation 
in cortical bone; cyclic loading at high physiologic strain rates causes more damage 
than at low strain rates(21). Osteoporosis treatments alter the fatigue properties as well. 
In two recent studies, fatigue life was increased following anabolic osteoporosis 
treatment, but the resistance of cortical bone to failure declined with catabolic 
osteoporosis treatment(22,23). 
 
Limited data are available for the fatigue behavior of cancellous bone. As for 
conventional materials, cancellous fatigue life declines with an increase in applied 
strain magnitude. In addition, microcrack propagation in cancellous bone under 
fatigue loading is determined by tissue heterogeneity not by local tissue stress. 
Damage was formed near the centers of trabeculae instead of at the surfaces or near 
the remodeling cavities,  indicating the differences in tissue properties at centers and 
surfaces were dominant for crack propagation(24). Furthermore, fatigue damage was 
not generated throughout the tissue, but was concentrated at a limited number of 
locations far from the tissue surface, suggesting that the damage sites contain older 
less remodeled tissue(25). 
 
In addition to bone strength and fatigue strength, fracture toughness, correlates with 
bone fragility, characterizes the ability of a material to withstand a crack without 
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brittle fracture occurring. The mechanical properties from monotonic loading and 
fatigue tests are obtained assuming that no unusual cracks are present in the material. 
However, cracks do exist in most bone tissue and affect failure. Therefore, 
understanding the ability to resist crack growth is essential. Fracture toughness is 
determined by the tension, bending, or cyclic loading of a sample with a notch that 
localizes crack formation(26,27). Measured values depend on the notch direction and 
microstructures(4,5,28). For example, transverse fracture toughness is higher than 
longitudinal fracture toughness(28,29). Fracture toughness has been positively correlated 
with osteon density but negatively correlated with bone porosity(4,5). Moreover, as 
crack propagates in bone tissue, fracture toughness increases(26,27). 
 
These three tissue properties (bone strength, fracture toughness, and fatigue strength) 
are independent but correlated with each other(30). Based on the common clinical 
fracture modes, the differential effects of alterations in these three tissue properties 
have been noted(31). For example, the prodromal symptoms and radiographic 
appearance of atypical femoral fractures (AFF) are similar to those of stress fractures 
and thus suggest fatigue failure. AFFs are characterized by a unique transverse 
fracture line and bilateral occurrence(32), occurring under normal loading conditions 
such as walking in postmenopausal women. AFFs occur in the cortex at a location that 
normally does not easily fracture, indicating high whole-bone strength, and have been 
suggested instead to be caused by fatigue loading with accumulated microdamage and 
insufficient fracture toughness. The fracture trajectory is a transverse crack growth, 
consistent with impaired fracture toughness rather than insufficient bone strength(33,34).  
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1.4   Nanomechanics and Tissue Composition of Bone 
 
To characterize tissue-level mechanical properties and composition, nanoindentation, 
Raman spectroscopy, FTIR, and Second Harmonic Generation spectroscopy (SHG) 
are being discussed here. Tissue mechanical properties such as indentation modulus 
and hardness are determined by nanoindentation. Quasistatic nanoindentation tests are 
performed by loading and unloading an indenter of a known geometry into the sample 
while recording load-displacement data. Indentation modulus (Ei) and hardness (H) 
can be determined from load-displacement curves with Oliver-Pharr method(35). 
Nanoindentation has been used to characterize tissue mechanical properties in a 
submicron length scale such as lamellar, interstitial and osteonal tissue(10,11).  
 
Tissue composition such as mineral-to-matrix ratio, carbonate substitution, collagen 
maturity, and crystallinity can be examined by Raman spectroscopy and FTIR. Both 
instruments provide complimentary composition data about the mineral and organic 
phases of bone. Raman spectroscopy has higher resolution and can be performed on 
bulk samples whereas FTIR needs thick sections. Inelastic scattered light, interacting 
with vibrated molecular bonds in the sample, is collected by Raman spectroscopy, 
whereas, FTIR measures light absorption by the bonds of a vibrating molecule. Tissue 
composition can be determined from peak height or peak area ratio of specific 
wavelengths associated with particular chemical bonds or compositions. In addition to 
Raman spectroscopy and FTIR, SHG microscopy measures aligned collagen content 
associated with higher tissue stiffness(36). SHG creates a map of aligned collagen 
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content with nonlinear scattering photons from aligned collagen fibers within bone. 
These measurements distinguish whether the collagen is aligned within the 
plane(8,36,37). The alignment of the collagen was positively correlated with tissue 
strength(38).  
  
Spatial distributions in tissue composition, tissue age, cause similar variations in 
nanomechanical properties. In human cortical bone, osteons have lower stiffness and 
hardness compared to more mineralized and older interstitial tissue(7). Similarly, in 
cancellous bone, stiffness and hardness are lower on the surface of a single trabecula 
compared to the center of the trabecula(11). Additionally, the correlations between 
tissue mechanical properties and composition have been examined(11). For example, 
tissue stiffness and hardness are positively correlated with mineralization(8,39). These 
nanomechanical properties also follow trends in greater aligned collagen content(11). 
 
1.5   Osteoporosis and Aging  
 
Osteoporosis is an age-related disease, caused by loss of estrogen in women at 
menopause(40). Estrogen regulates the rate and balance of remodeling. A negative 
balance of bone mass develops, with more bone resorbed than formed in each 
remodeling cycle, due to the loss of estrogen. In addition to estrogen loss, activation 
frequency of bone multicellular units (BMUs), the number of new BMUs created per 
unit volume per unit time(41), is age-dependent(42). Activation frequency of BMUs 
declines from childhood to a minimum at about age 35, and then rises and falls again 
at the end of life-span(43) (Figure 1.4). As a result of loss of estrogen(44) and increased 
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activation frequency, bone mass drops rapidly with postmenopausal type I 
osteoporosis in women.  
 
 
Figure 1.4 Activation frequency of BMU versus human age. Figure adapted from  
                  Martin et al.(42).  
 
 
With age, apparent level strength and stiffness of cortical and cancellous bone both 
decline resulting from increased porosity and decreased apparent density (45,46). Osteon 
numbers increase, and osteon dimensions are altered(47,48). For example, in aging 
humans, osteonal area tends to decrease, which might reflect the higher probability 
that larger osteons are remodeled(49). Haversian canal area tends to increase(42), which 
could result from reduced osteoblast lifetimes or reduced apposition rates(50). 
 
In addition to microstructural alteration, osteoporosis alters tissue composition and 
nanomechanical properties as well. Bone tissue mineralization was reduced, carbonate 
substitution and crystallinity were increased in ovariectomized animal models and 
patients with osteoporotic fractures(51,52). Few studies have examined changes in 
mechanical properties with osteoporosis; however, they appear not to change. 
Indentation modulus and hardness did not differ between normal and osteoporotic 
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patients(53). Moreover, due to different metabolic activities in cortical and cancellous 
bone, mechanical properties with osteoporosis in each bone type would be affected 
differently(54,55).  
 
1.6   Osteoporosis Treatment and Its Effects on Bone Tissue Properties 
 
Anti-resorptive agents used to treat osteoporosis include bisphosphonates such as 
alendronate, zoledronate, and risedronate, selective estrogen receptor modulators 
(SERMs, tamoxifen and raloxifene), and antibodies to RANKL (denosumab). The 
most commonly prescribed class of antiresorptive therapy is the bisphosphonates. 
These agents are quite effective and reduce osteoporotic fractures by 40% to 50%(56). 
Inhibiting resorption overcomes the deficits in bone mass associated with insufficient 
bone formation during elevated bone remodeling. These treatments are intended to 
reduce elevated bone turnover rates to normal levels, thereby improving bone strength 
and reducing the incidence of fracture. 
 
Apparent strength and stiffness of bone tissue are increased with bisphosphonate 
treatment(57). Fatigue life under cyclic compressive loading, however, was reduced in 
bisphosphonate-treated osteopenia sheep compared to PTH-treated group(22). This 
reduction could be due to several factors including altered tissue properties, decreased 
heterogeneity of the properties or microdamage accumulation. At the tissue-level, 
indentation modulus, hardness and mineral-to-matrix ratio were increased with 
bisphosphonate treatment in sheep (11). Tissue heterogeneity was decreased as 
measured by Fourier transform infrared spectroscopy (FTIR) imaging(58). Furthermore, 
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bisphosphonate use is associated with microdamage accumulation, resulting in loss of 
toughness and fatigue life(22,59). The effects of long-term suppression of bone turnover 
on bone mechanical properties are not well understood, particularly whether the lack 
of bone turnover has consequences for tissue renewal and the repair of tissue damage. 
In fact, AFFs are associated with long-term bisphosphonate use, suggesting an adverse 
effect of the prolonged suppression of bone remodeling(32). Although the mechanism 
of AFF is unknown and has been suggested to reflect damage accumulation due to 
inadequate tissue renewal, other factors such as lower-limb geometry(60) and loading 
also may contribute to their development. 
 
In addition to catabolic osteoporosis treatment, two anabolic osteoporosis treatments 
are currently approved by the Food and Drug Administration (FDA): teriparatide 
(PTH [1-34]) and abaloparatide (PTHrP analog). Both anabolic treatments increase 
bone turnover and stimulate osteoblasts more than osteoclasts (Figure 1.5), opposite to 
the mechanism of anti-resorptive treatments(61). The life span of osteoblasts is 
prolonged, the number of osteoblasts is increased, and bone formation is stimulated(62-
65). The effect of PTH depends on the injection frequency. When PTH is administered 
continuously, bone resorption increases. However, if PTH is given intermittently, bone 
formation increases(66). 
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Figure 1.5 Intermittent PTH administration stimulated osteoblasts more than  
                  osteoclasts. Figure adapted from Gallacher et al.(61). 
 
 
PTH decreases fracture risk at both vertebrae and hip by over 50%(67). On average 
BMD increases by 10-14%(68,69). Regarding microstructural features, trabecular 
thickness and connectivity increase with PTH treatment whereas bisphosphonate 
treatment only stabilizes and preserves trabecular architecture(68,69). In cortical bone, 
however, changes are not as evident with PTH treatment as in cancellous tissue due to 
different metabolic activities. Elevated endocortical remodeling with PTH treatment 
slightly decreases cortical BMD and increases cortical porosity(69). Biomechanical 
properties, however, are not altered. Periosteal apposition increases cortical diameter 
and thickness, balancing out the BMD reduction biomechanically(69).  
 
Many studies also have examined apparent mechanical properties in small animal 
models with PTH treatment. Bone strength was increased with PTH treatment in intact 
animal models(70,71). Furthermore, PTH increased bone strength at the femoral neck 
and vertebra in ovariectomized rat models(72,73). Fewer studies have examined changes 
in mechanical properties with PTH treatment in large animal models(74-76). The 
proximal femur was stronger with PTH treatment compared to ovariectomized 
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monkeys; even after withdrawal of 6 months, the treatment effect was still retained(76). 
In addition, a study utilizing tissue from the exact same sheep from Chapter 2 and 
Chapter 3 has demonstrated prolonged fatigue life of cortical bone with PTH treatment 
compared to bisphosphonate treatment (22). However, its effect on bone tissue 
composition should also be examined to fully understand the mechanisms contributing 
to fracture.  
 
1.7   Simulation on Mechanical Behavior of Bone Tissue 
 
As the ability to image the skeleton in vivo has improved, the data acquired for 
additional noninvasive analyses have become important resources. Over the past 
decade, computational methods have been developed to simulate the mechanical 
behavior of the skeleton in healthy individuals. These approaches are noninvasive and 
inexpensive. Using in vivo CT of bone, the patient’s specific skeletal geometry is 
converted to a three-dimensional computational model that can simulate a mechanical 
test and identify fracture risk(77). This approach captures not only the overall bony 
geometry of sites such as the hip, spine, or distal radius, but also the relative material 
properties of cancellous bone (Figure 1.6). Quantitative CT values for cancellous bone 
can be converted to tissue density and is related to tissue stiffness in the laboratory(78). 
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Figure 1.6 Illustration depicts a three-dimensional finite element model of a vertebral  
                  body developed from CT image data with the front quarter removed. The  
                  red line shows the geometric outline of the vertebra. The cubes are  
                  individual finite elements, and the gray scale represents different material  
                  properties. The individual CT voxels are converted to finite elements with  
                  variable material properties based on the attenuation values from the scan. 
 
 
The finite element method (FEM) is a computational technique used to perform 
mechanical analyses. Complex geometries and material distributions are analyzed by 
replacing a continuous structure with a discrete model structure of small subunits 
(finite elements) whose mechanical behavior is defined well. The discretization 
(geometric representation and element characteristics), boundary conditions (applied 
loading and interfaces), and material properties (generally, linear and elastic) 
determine the quality of the model solution. Because FEM requires discretizing a 
complex geometry, the conversion of image voxels from CT to a geometric finite 
element model is straightforward, and bone material properties can be assigned to each 
element based on CT attenuation values. When loads are applied to the model to 
simulate the in vivo activities of interest, the simulation predicts the mechanical 
behavior of the model. Even though FEM analysis requires computational time, this 
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noninvasive method can capture complex loading conditions and geometries; thus 
predicting fracture locations well when compared with the reference of mechanical 
testing(79).  
  
Another simulation approach focusing on crack propagation and crack tip analysis is a 
quasi-automated computer code based on finite element method (FRacture Analysis 
Code)(80). FRANC automatically meshes in an arbitrary region in which a crack 
propagates and calculates the driving force in front of the crack tip regardless of the 
mixity of fracture modes(81,82) (Figure 1.7). In addition to automatically re-meshing 
around the crack tip without losing unaffected structure information, other main 
features of FRANC are predicting crack trajectory, calculating the local stability and 
stress intensity factor. Displacement correlation(83,84), modified crack closure 
integral(85), and the equivalent domain correlation(86) approaches are different methods 
to calculate stress intensity factors. All methods generate accurate results(87) whereas 
the latter two approaches are more reliable when the cracks are under complex mixed-
mode loading(80). Furthermore, FRANC overcomes the limitation of current FEM 
simulation software that lacking ability to continuously re-mesh the model to 
accommodate incremental crack extension.  
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Figure 1.7 Illustration of FRANC2D model with re-meshing along the crack tip 
(shown in red). 
 
 
1.8 Study Objectives and Significance 
 
Osteoporosis is a bone disease associated with fracture, due to an imbalance in bone 
remodeling favoring bone resorption.  Bone quantity and quality are decreased with 
osteoporosis(11,52,88,89). Parathyroid hormone (PTH), an FDA-approved anabolic 
osteoporosis treatment, increases bone mass in animal studies(62,71,75), but its effect on 
bone tissue composition and mechanics is unknown. Moreover, few studies utilize 
larger animal models with Haversian remodeling that better capture the dynamics of 
human bone tissue. Sheep experience a similar aging process including menopause 
and reproductive hormone profile as human does(90,91). In this research, osteopenia was 
induced in mature sheep using ovariectomy combined with a metabolic acidosis diet 
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for two years. During the second year, sheep were treated with PTH (PTH, n = 7, 
5µg/kg/day) or saline (vehicle, n = 6).  
 
For the first objective, the alterations of mechanical and material properties of cortical 
bone with PTH treatment in an osteopenia sheep model were examined. We 
hypothesized that PTH would increase bone mass and elevate tissue properties to 
resist bone failure due to altered tissue composition. We performed multi-scale 
analysis to determine the contribution of tissue-scale material changes to whole bone 
mechanical behavior. Whole-bone mechanical performance and morphology (bending 
strength, bending stiffness, and cross-sectional moment of inertia) were determined in 
femurs using four-point bending tests and CT scans. Millimeter-scale specimens of 
cortical bone from the mid-shaft of right femur were used to determine tissue fatigue 
strength and fracture toughness. Nano-scale characterization of cortical bone tissue 
included nanoindentation, Raman spectroscopy, and second harmonic generation 
microscopy (SHG). The correlation among whole bone bending strength, fatigue 
behavior, and fracture toughness were determined. This study is the first to compare 
and correlate all three mechanical failure properties: whole bone strength, fatigue 
behavior, and fracture toughness.  
 
For the second objective, the effects of PTH treatment on bone tissue composition and 
mechanics of cancellous bone in an osteopenia sheep model were investigated. We 
hypothesized that PTH would increase tissue heterogeneity and preserve mechanical 
properties during cyclic loading through architectural and compositional changes. In 
each animal two cancellous samples were taken from the distal femur: one for 
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monotonic loading and one for cyclic fatigue loading. Samples were subjected to 
microCT scanning and individual trabecular segmentation (ITS) to determine volume 
fraction of rod- and plate-like trabeculae. Then specimens were failed in compression 
to determine cancellous bone strength or cyclic loading to evaluate fatigue life and 
energy dissipation. Cancellous tissue mechanics and composition were analyzed by 
nanoindentation and Raman spectroscopy. In addition, specimens from iliac crest and 
vertebra were obtained for characterizing PTH effect on bone quality and tissue 
heterogeneity with histomorphometry, FTIRI and a novel nanoscale infrared technique 
called AFM-IR. All the experimental sheep were subjected to bone density and serum 
measurements.  
 
Our third objective was to use a computational mechanics approach to investigate the 
role of anisotropy of fracture toughness and of altered microstructure in crack 
trajectory and the energy of propagating a crack in cortical bone. Previous simulations 
demonstrated that strength and fracture properties of osteons affected crack 
propagation(92-94), mostly based on isotropic fracture toughness. Anisotropic fracture 
toughness is more representative of bone, but difficult to measure. Simulations were 
performed because limited experimental data are available for anisotropic fracture 
toughness. A 2x20 mm pre-notched (0.05 mm initial crack on tensile side) beam was 
created in Franc2D and loaded in 3-point bending. We altered anisotropic fracture 
toughness of osteon, osteon location, number and diameter for different simulation 
cases. Crack trajectory was examined, and normalized critical load was calculated, 
indicating the load needed to propagate a unit length of a crack. Investigating the role 
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of microstructure and anisotropy of fracture toughness in crack propagation 
simulations provided additional insight into crack propagation mechanisms in bone 
and ultimately understanding bone fragility.  
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CHAPTER 2 
EXPLAINING THE EFFECTS OF PTH TREATMENT IN CORTICAL BONE 
IN A SHEEP MODEL OF OSTEOPOROSIS: CONTRIBUTIONS OF WHOLE 
BONE STRENGTH, FATIGUE BEHAVIOR AND FRACTURE TOUGHNESS* 
 
 
2.1   Introduction 
 
Osteoporosis-related fractures affect an estimated two hundred million people 
worldwide.(1) Patients with a prior osteoporosis-related fracture are at increased risk of 
experiencing a subsequent fracture.(2) Understanding the main contributors to skeletal 
fragility can improve fracture risk prediction. Bone mineral density (BMD), as 
measured by dual-energy x-ray absorptiometry, is the standard method of assessing 
fracture risk; however, BMD has known limitations, particularly in patients taking 
pharmaceuticals to address osteoporosis.(3)   
The ability of a whole bone to resist fracture is determined by bone tissue 
mass, internal structure, and material properties.(4) Cortical bone carries a major share 
of the total load of the skeleton particularly in the long bones. Structural properties and 
intrinsic material properties of cortical bone determine its mechanical competence. 
Measures of BMD are sensitive to some structural properties of bone (mass and 
density), but not to variations in internal microstructure, tissue properties, or tissue 
composition.  
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Mechanical failure of a whole bone may occur from a single load, which is 
sensitive to whole bone strength, from cyclic loading that is sensitive to fatigue 
behavior, or from sensitivity to crack growth, reflected by fracture toughness.(5) 
Fatigue behavior is the resistance to failure following many cycles of loading at levels 
well below the tissue strength, quantified as fatigue life. Fracture toughness is a 
material property that determines the resistance to crack growth at a stress 
concentration, measured in a standard three-point notch bending test. Whole bone 
strength, fracture toughness and fatigue behavior are interdependent,(6) and may have 
differential contributions to clinical fractures. For example, consider atypical femoral 
fractures (AFF), associated with long-term use of bisphosphonates. AFFs occur in a 
relatively dense cortical shell, indicating higher whole-bone strength compared to 
other bone tissue, but are believed to be caused by fatigue loading with accumulated 
microdamage and insufficient fracture toughness.(7) The fracture trajectory is a 
transverse crack growth, consistent with impaired fracture toughness rather than 
insufficient whole-bone strength.(8,9) Therefore, for a full understanding of resistance to 
fracture, one may need to examine whole bone strength, fracture toughness and fatigue 
behavior, as a function of changes in tissue composition due to either osteoporosis or 
therapeutics.  
Several therapeutic approaches have been developed to treat osteoporosis by 
inhibiting bone resorption, or by enhancing bone formation.(10) In the current study, we 
focused on intermittent parathyroid hormone treatment (iPTH), an anabolic 
osteoporosis treatment that is approved for use in the US. PTH stimulates bone 
formation.(11) Treatment with PTH in animals led to increases in the fatigue life of 
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cortical bone(12) and increases in bone tissue strength.(13,14) The physical mechanism 
behind PTH-induced improvement in bone tissue mechanical properties is not yet 
known. 
Cortical bone tissue strength, fracture toughness, and fatigue behavior are 
influenced by tissue heterogeneity and ultrastructure. In cortical bone in primates, 
material properties and nanomechanical properties vary due to tissue age in the 
osteon.(15,16) Tissue age is different from animal age resulting from remodeling process. 
Osteonal tissue is less mineralized and less stiff compared to interstitial matrix, which 
is primary bone tissue and has been present longer than osteonal tissue.(17) Through 
remodeling, tissue age can vary within an osteon. Tissue near the cement line has a 
slightly greater tissue age since it is formed first during remodeling.(18) These 
variations in tissue properties are important because fracture resistance is affected by 
local tissue properties. In addition, osteonal boundaries can influence the propagation 
of cracks and thereby contribute to tissue fatigue strength and fracture toughness.(19) 
The cement line in cortical bone tissue can serve as a toughening mechanism by 
deflecting crack propagation.(20) Hence, changes in tissue age and osteon density 
associated with bone remodeling may contribute to the ability of whole bone to resist 
fracture. 
The objective of this study was to determine the effects of PTH on three 
metrics of bone mechanical performance (whole bone bending strength, fracture 
toughness, fatigue life) and to determine how tissue properties including nanoscale 
composition and mechanical properties contribute to whole bone bending strength. An 
ovine model was used because sheep undergo osteonal remodeling, thereby providing 
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a spatial material composition analysis similar to that of humans. In addition, hormone 
profiles of sheep are similar to those of women, especially the reproductive cycle 
during the breeding season.(21) We hypothesized that PTH would increase bone mass 
and elevate tissue properties to resist bone failure due to altered tissue composition in 
an ovine osteoporosis model.  
 
2.2   Methods 
 
2.2.1   Animal model 
 
The present study utilized 13 mature Swiss Rambouillet ewes (6-7 years old, 
weighing 69-82 kg). All sheep were ovariectomized (OVX) and placed on a metabolic 
acidosis (MA) diet for one year to induce osteopenia.(22) All sheep in the present study 
were ovariectomized at the same time point to limit the effects of seasonal variations 
in bone mass (23). One year following OVX and MA diet, the sheep were assigned to 
two treatment groups: (1) PTH group (n = 7): daily parathyroid hormone treatment 
(teriparatide 1-34, generously provided by Eli Lilly, 5µg/kg/day subcutaneous 
injection) and (2) Vehicle group (n = 6): daily saline vehicle injection for 12 months. 
Sheep remained on the MA diet during the 12 months of treatment. All animal 
procedures were reviewed and approved by the IACUC of the University of 
Minnesota (# 0907A68881) and the Hospital for Special Surgery (#11-09-02E).  
Ewes were monitored by DEXA, and double labeled with tetracycline 4 and 9 
days prior to euthanasia. Serum calcium levels, PTH levels, alkaline phosphatase 
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activity (ALP) and bone markers (BAP and CTx) were monitored quarterly throughout 
the study. Iliac crest biopsies (n = 2/sheep) were obtained from all sheep before 
transition to the treatment groups (after 12 months) and again at euthanasia (at 24 
months). Images were collected with microCT for cortical bone volume fraction 
(BV/TV), tissue mineral density (TMD), and thickness (Ct.Th).  
After euthanasia, femurs were harvested, wrapped in gauze soaked with PBS, 
and stored at -20 °C prior to specimen preparation. The right femur was preserved to 
assess cortical bone tissue, and the left femur was used for whole bone biomechanical 
analysis.  
 
2.2.2   Cortical Bone Tissue: Fracture toughness and fatigue life 
 
Cortical beams (n = 6-7/group) were created from the medial diaphysis of the 
right femurs, parallel to the long axis of the bone, using a low-speed diamond saw 
(Buehler Isomet; Lake Bluff, Illinois, USA). Beams were then polished using 15, 5, 
and 1 micron lapping films to a final size of 2 x 2 x 25 mm. Ethylene glycol was used 
as a lubricant to prevent mineral leaching.(24,25) After polishing, samples were notched 
(~200 µm deep) with a razor blade under irrigation with 1 µm diamond suspension. 
The orientation of the notch was transverse relative to the osteonal direction. Beams 
were stored at -20°C in saline-soaked gauze until testing. 
 Fracture toughness of cortical bone was determined using the notched three-
point bending approach. The beams were thawed in PBS at 37°C for 3 hours before 
testing. The samples were placed in fixtures within a material testing device (Bose 
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Electroforce LM-1; Eden Prairie, Minnesota, USA) with a 20 mm span between the 
lower support rods. A compressive displacement rate of 0.015 mm/s was applied to 
failure. The critical load was determined, and transverse fracture toughness was 
calculated using the ASTM E399 standard.(26) Each fracture test was recorded using a 
high-speed camera (4000 fps with 248 µs exposure time). Total crack length was 
determined from a single frame of the video that showed the entire crack trajectory.   
 To examine the microstructure of the crack plane, rectangular prism-shaped 
specimens were cut about 2 mm below the fracture surface with a low-speed diamond 
saw and parallel to the long axis of the bone. The fracture fragments were soaked in 
ethanol, dehydrated, and coated with gold/palladium before SEM imaging at 5kV 
(Mira 3, Tescan, Czech Republic). Osteon density (number of osteons per 1x1 mm2) 
was calculated from the SEM images.  
To allow consideration of fatigue behavior, we include fatigue data from 
specimens previously reported by Brock and colleagues that were harvested from the 
same animals.(12) In those experiments, rectangular beams (2 x 2 x 25 mm beams, n = 
6/group) were cycled between 400 and 4000 µε under load control until failure. 
During testing samples were hydrated with hydroxyapatite-buffered PBS at 37 ˚C. 
Fatigue life, determined by Brock and colleagues, was included to correlate with 
fracture toughness, whole bone bending strength and tissue nanomehcanics and 
compositions in the current study.  
 
2.2.3   Nanoscale tissue characterization 
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A 15-mm thick segment was removed from the mid-diaphysis of the right 
femur. The segment was dehydrated in ethanol and embedded in polymethyl 
methacrylate (PMMA). A 3-mm slice was cut from the embedded segment. The slice 
was polished anhydrously to a final root-mean-square surface roughness less than 15 
nm over a 5 x 5 µm2 scan, as verified using atomic force microscopy (Dimension 
3100, Veeco Metrology Group).(24) Three osteons per sample and three radial lines per 
osteon were chosen for tissue-property characterization by nanoindentation, Raman 
spectroscopy, and second harmonic generation microscopy (SHG).(15) To reduce 
variations caused by anatomical location, osteons were selected from the postero-
lateral quadrant.   
 Nanoindentation was used to characterize tissue nanomechanical properties.(27) 
A 20 x 20 µm2 surface topography scan was acquired prior to indentation to accurately 
identify the center of each lamella. Indentations were made (TriboIndenter, Hyistron 
Inc., Minneapolis, MN) with a Berkovich diamond indenter in the middle of each 
lamella, moving away from the center of each osteon. Three osteons were selected, 
resulting in 45-135 indentations per animal. Indentation loading occurred at a rate of 
50 µN/s, a 10-second hold at 700 µN, and unloading at 50 µN/s. The resulting 
indentations were ~150 nm deep. The indentation modulus and hardness were 
calculated from the unloading part of the load-displacement curve following Rho et 
al..(28)  
 Tissue composition was characterized by Raman spectroscopy. As described 
previously, data were collected at the same mid-lamellar locations probed by 
nanoindentation.(15) The white light optical microscope attached to the Raman 
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spectroscope (InVia microRaman, Renishaw, Gloucestershire, United Kingdom) was 
used to identify the residual indents and center the laser spot (~2 µm2) over each 
residual indent. Spectra were collected between 800 and 1800 cm-1 with background 
fluorescence removed using WiRETM V4.0 software (Renishaw). Tissue mineralization 
(mineral:matrix), B-type carbonate substitution (carbonate:phosphate), and 
crystallinity were calculated as described previously.(15)  
 Aligned collagen content associated with tissue stiffness was determined by 
SHG (Mai Tai Deep See, Spectra Physics, Santa Clara, CA).(29) A map of aligned 
collagen content within each osteon was created. The square root of SHG intensity is 
proportional to the aligned collagen within the transverse plane.(30) SHG intensity was 
averaged for a window 1 pixel wide and 4 pixels high (497 x 1988 nm2, Image J, 
National Institutes of Health) along a radial line from the center of each osteon. For 
each lamella, maxima corresponded to lamellar aligned collagen and minima 
corresponded to interlamellar aligned collagen.(15) Peak height ratio, representing the 
variation in the amount of aligned collagen and a measure of inhomogeneity, was 
calculated as the ratio of the intensity of lamellar-to-interlamellar aligned collagen. 
 
2.2.4   Whole bone strength and geometry 
 
Computed tomography (135 kV, 260 mAs, Toshiba Aquilion LB) was used to 
quantify whole bone geometry. CT images of the left femurs (n = 6-7/group) were 
collected before conducting four-point bending. Scans of a 3-cm thick segment of the 
mid-diaphysis were used to calculate the moment of inertia about the caudal-cranial 
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direction as described previously.(31)  
Whole-bone mechanical behavior of the left femur was determined by four-
point bending to failure in the caudal-cranial direction (858 Mini Bionix, MTS; 
5mm/min loading rate; 13 cm upper span width; 22 cm lower span width). Bending 
stiffness and whole bone bending strength were calculated from the load-displacement 
data.   
 
2.2.5   Data analysis 
 
Analysis was performed on the raw, unaveraged data from all data sets (JMP 
11.0, SAS Institute, INC.). Repeated nested ANOVA determined the effects of 
treatment and tissue age on cortical tissue properties from nanoindentation, Raman 
and SHG. Generalized linear models with treatment (PTH or Vehicle), osteon (1-3, 
nested variable), radial line (1-3, nested variable), and distance from the center of the 
osteon (0-70µm) were used. In addition, data were binned in 7 µm increments across 
the radius in three randomly-selected osteons per animal to visualize tissue age data.  
The effects of PTH treatment on the micro- and whole-bone (fracture 
toughness, osteon density, total crack length, moment of inertia, bending strength, 
bending stiffness) outcome measures were analyzed by Student’s t-test. A p-value less 
than 0.05 was considered significant. Group difference presented are significant unless 
noted otherwise. To determine the contributions of compositional variations to 
alterations in tissue properties and correlations between strength, fracture toughness 
and fatigue life, multi-variable regression analysis was performed with averaged 
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values from each data set.  
 
2.3   Results 
 
The average weight of the sheep in the PTH treatment group was 28 lb lower 
than the Vehicle group at 24 months (Table 2.1). BV/TV, TMD and Ct.Th of cortical 
bone from the iliac crest were not different between treatment groups (Table 2.1). 
Serum PTH levels were 0.26 pg/ml greater in the PTH group compared to Vehicle at 
24 months. Serum CTx levels were slightly greater by 34.4% with PTH treatment 
relative to Vehicle (p < 0.1). Serum levels of calcium, and BAP and ALP levels were 
not different between the two groups (Table 2.1). 
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Table 2.1 Reductions in body weight were present in the PTH-treated group before  
                 treatment started and remained at the end of treatment. Serum PTH at 24  
                 months was higher in the PTH treatment group. Changes in serum CTx had  
                 a trend towards increasing with PTH treatment. 
                 Data shown as mean (SD). *p < 0.05. **p < 0.1 
     Ct.Th  (µm) 
    Cortical TM
D (mg/cm
3) 
    Cortical BV/TV  
  Iliac crest structure 
    PTH (pmol/L) 
    ALP (U/L) 
    CTx (ng/mL) 
    BAP (U/L) 
    Calcium (mmol/L) 
  Serum markers 
    Body mass (lb) 
  Sheep characteristics 
 
 
Not applicable 
 0.05 (0.12) 
80 (54) 
0.56 (0.3) 
34 (15) 
1.1 (0.07)  
163 (7.7) 
 
Vehicle Baseline 
 (0 mo.) 
0.03 (0.08) 
46 (26) 
0.59 (0.2) 
25 (10) 
1.0 (0.04) 
165 (8.3) 
PTH 
272 (73) 
714 (19) 
0.79 (0.09)  
0.22 (0.17) 
54 (29) 
0.41 (0.2) 
43 (34) 
0.74 (0.27)  
186 (8.0) 
 
Vehicle 
1 year after ovariectomy 
(13 mo.) 260 (62) 
730 (40) 
0.78 (0.08) 
0.11 (0.15) 
52 (32) 
0.64 (0.5)** 
44 (25) 
0.89 (0.27) 
166 (12)* 
PTH 
275 (61) 
698 (35) 
0.76 (0.18)  
0.05 (0.12) 
110 (51) 
0.18 (0.1) 
35 (15) 
1.2 (0.11)  
186 (11) 
 
Vehicle 
1 year after treatment 
 (24 mo.) 312 (82) 
725 (43) 
0.82 (0.06) 
0.31 (0.18)* 
62 (34) 
0.86 (1.6)** 
23 (9.3) 
1.1 (0.05) 
158 (20)* 
PTH 
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The effect of PTH treatment on the femur was apparent at the micro- and 
nanoscale (Table 2.2). Fracture toughness was 22.4% lower in the PTH-treated sheep. 
Osteon density was 120% greater in the PTH group (Figure 2.1). Total crack length 
was not different between groups. Tissue indentation modulus was 4.3% lower in the 
PTH-treated group (Figure 2.2). Hardness was 10.8% less on average with PTH 
treatment (Figure 2.2). Hardness and indentation modulus did not vary with tissue age 
within osteons (Figure 2.2).  
 
Table 2.2 PTH treatment reduced indentation modulus, hardness, and carbonate  
                 substitution. Mineral-to-matrix ratio and peak height ratio were increased  
                 with PTH treatment, which also increased with tissue age. In addition to  
                 nano-scale tissue properties, fracture toughness was decreased and osteon  
                 density was increased with PTH treatment compared to Vehicle group.           
                Data shown as mean (SD). *p < 0.05. NS = not significant. NA = not  
                applicable 
 
            Treatment effect 
Vehicle        PTH 
Tissue nanomechanics   
   Indentation Modulus (GPa) 28.0 (4.6) 26.8 (3.6)* 
   Hardness (MPa) 992 (200) 885 (150)* 
Tissue composition   
   Mineral : matrix 6.83 (0.70) 7.38 (0.84)* 
   Carbonate : phosphate 0.213 (0.01) 0.209 (0.01)* 
   Crystallinity 0.038 (0.001) 0.038 (0.001) 
   Aligned collagen content 1.79 (0.62) 2.38 (0.96)* 
Cortex properties    
   Fracture toughness (MPa√m) 6.24 (0.81) 4.82 (1.3)* 
   Osteon density (#/mm2) 12.5 (5.3) 27.4 (11)* 
   Total crack length (pixels)   63.2 (11) 58.3 (9.0) 
   Diaphyseal moment of inertia (cm4)  1.70 (0.58) 2.11 (1.1) 
   Whole bone bending stiffness (N-m2) 91.7 (17) 110 (19) 
   Whole bone bending strength (N-m) 145 (24) 162 (40) 
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Figure 2.1 Osteon density was increased with PTH treatment as shown in SEM  
                  images (A) Vehicle group (B) PTH group. Field of view 1 x 1 mm2. 
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Figure 2.2 Nanomechanical properties (indentation modulus and hardness) decreased  
                  with PTH treatment but not tissue age. (A) Indentation modulus (p = 0.18)  
                  and (C) hardness (p = 0.33) versus tissue age. Percent distance away from  
                  the center of osteon represents older tissue age. (B) Indentation modulus (p  
                  < 0.0001) and (D) hardness (p < 0.0001) with vehicle/PTH treatment.  
                 Each point in (B) and (D) is the average value of multiple nanoindentation  
                 measurements of per sheep (45-135 measurements per animal). Red circles  
                 with solid lines represent PTH group and blue triangles with dashed lines  
                 represent Vehicle group. 
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Mineral-to-matrix ratio in the osteons was influenced by both treatment and 
tissue age (Figure 2.3). Mineral-to-matrix ratio was 8.1% greater in PTH-treated 
animals, and for a total increase of 4.8–9.6% across the osteon radii. The carbonate-to-
phosphate ratio in osteons also was reduced in PTH-treated animals (Figure 2.3). 
Crystallinity did not vary within the osteon with either PTH-treatment or tissue age 
(Figure 2.3). Aligned collagen content varied with treatment and tissue age (Figure 
2.4). The peak height ratio of lamellar-to-interlamellar aligned collagen increased by 
24.8% in PTH-treated animals, and for a total increase of 5.7–11.4% across the osteon 
radii.  
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Figure 2.3 Mineral-to-matrix ratio increased with tissue age and PTH treatment while  
                  carbonate substitution decreased with PTH treatment. (A) Mineral-to- 
                  matrix ratio (p < 0.0001), (C) carbonate substitution (p = 0.29) and (E)  
                  crystallinity (p = 0.11) versus tissue age. Percent distance away from the  
                  center of osteon represents older tissue age. (B) Mineral-to-matrix ratio (p  
                  < 0.0001), (D) carbonate substitution (p < 0.0001) and (F) crystallinity (p  
                  = 0.70) with vehicle/PTH treatment. Each point in (B), (D), (F) is the  
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                  average value of multiple Raman measurements for a single sheep (5-15  
                  indents per line, 3 lines for 3 osteons per sample, corresponding 45-135  
                 measurements per animal). Red circles with solid lines represent PTH  
                 group and blue triangles with dashed lines represent Vehicle group. 
 
 
 
Figure 2.4 The degree of aligned collagen (peak height ratio) increased with tissue  
                  age but increased with PTH treatment. (A) Peak height ratio  
                  (lamellar/interlamellar aligned collagen, p < 0.0001) versus tissue age.  
                  Percent distance away from the center of osteon represents older tissue  
                  age. (B) peak height ratio (p < 0.0001) with vehicle/PTH treatment. Each  
                  point in (B) is the average value of multiple SHG measurements for a  
                  single sheep (45-135 measurements per animal). Red circles with solid  
                  lines represent PTH group and blue triangles with dashed lines represent  
                  Vehicle group. 
 
 
Whole bone structure and mechanical performance were not influenced by 
PTH treatment. Moment of inertia, whole bone bending stiffness and strength did not 
differ between PTH and vehicle groups. Whole bone bending strength was correlated 
with bending stiffness (r2 = 0.32).   
Correlations among three mechanical failure properties (whole bone bending 
strength, fatigue life, fracture toughness), compositional properties from Raman 
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spectroscopy, and nanomechanical properties from nanoindentation were present 
(Table 2.3, Figure 2.5). At the nanoscale, mineralization (mineral-to-matrix ratio) 
explained 85% of the variation in aligned collagen content. However, carbonate 
substitution and crystallinity were not correlated with nanoindentation properties. 
Neither indentation modulus nor hardness was correlated with mineral-to-matrix ratio. 
For correlations of tissue composition with micro- and macro-scale mechanical 
properties, mineralization explained 35% of the variation in fracture toughness and 
27% of the variation in fatigue life (Figure 2.6). Crystallinity explained 60% of the 
variation in whole bone bending strength. Whole bone bending strength was correlated 
with fracture toughness (r2 = 0.32). Together, 63% of the variation in whole bone 
bending strength was explained by crystallinity and fracture toughness. Fatigue life 
was not correlated with either whole bone bending strength or fracture toughness.  
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Figure 2.5 Correlations among three interdependent mechanical failure properties:  
                   whole bone bending strength, fracture toughness, and fatigue life.  
                   Fracture toughness was associated with bending strength (r2 = 0.32, P <  
                   0.05). Fatigue life, however, did not correlate with either fracture  
                   toughness or bending strength. Red circles represent PTH group and blue  
                   triangles represent Vehicle group. 
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Figure 2.6 Alterations in tissue composition contributed to tissue properties that  
                  describe bone failure. Red/blue background indicated properties  
                  increased/decreased with PTH treatment. 
 
 
Table 2.3 Crystallinity and fracture toughness explained 60% and 32% of the  
                 variations in whole bone bending strength respectively. Together,  
                 crystallinity and fracture toughness explained 63% of the variation in  
                 whole bone bending strength. *p < 0.05. **p < 0.1. (r2 of the correlations <  
                 0.25 was not reported) 
 
Predictor Independent variables   r2 
Whole bone bending strength Crystallinity 0.60* 
Fatigue life Mineralization 0.27** 
Fracture toughness Mineralization 0.35* 
Mineralization Aligned collagen content 0.85* 
Whole bone bending strength Fracture toughness 0.32* 
Whole bone bending stiffness Fracture toughness 0.56* 
Whole bone bending strength Crystallinity + Fracture toughness 0.63* 
Fracture toughness Mineralization + Whole bone bending strength 0.54* 
Fracture toughness Mineralization + Whole bone bending stiffness 0.67* 
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2.4   Discussion 
 
We hypothesized that PTH would alter tissue composition, and improve tissue 
mechanical properties and whole bone strength in this large animal model of 
osteoporosis. PTH treatment improved micro- and nano-scale mechanical properties. 
However, the effects of PTH treatment were not evident in macro-scale geometry or 
whole bone strength of the femur. 
Despite the fact that whole bone strength was not altered by PTH treatment, 
bone tissue mechanical properties were altered. Fracture toughness was decreased with 
PTH treatment. Although fracture toughness correlated with whole bone bending 
strength, the changes in fracture toughness were not evident at the whole bone level 
through differences in bending strength. Mechanical failure of a whole bone may 
occur from a single load, which is sensitive to whole bone strength, from cyclic 
loading that is sensitive to fatigue behavior, or from sensitivity to crack growth, 
reflected by fracture toughness.(5) The altered tissue properties measured here reflected 
alterations in fatigue life and fracture toughness, which would cause mechanical 
failure independent of whole bone strength changes. The three mechanical properties 
are often investigated independently, but are correlated with each other as all describe 
failure of molecular bonds. To date studies have not closely examined the correlation 
of these distinct mechanical properties in bone.  
Fatigue life is the resistance to many cycles of low- to moderate-magnitude 
loading whereas fracture toughness represents the energy needed to propagate a single 
pre-existing crack, a mechanism that contributes to both monotonic and cyclic strength 
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behavior. Previously, we showed increased fatigue life of cortical bone associated with 
PTH treatment compared to control and bisphosphonate-treated tissue.(12) Our data 
suggest that the increased fatigue life might be associated with increased tissue 
mineralization as measured by Raman spectroscopy (r2 = 0.27, p = 0.08). Decreased 
fracture toughness was also correlated with increased tissue mineralization (r2 = 0.35, 
p < 0.05). Crystallinity explained 60% of the variation in whole bone bending strength 
(Figure 2.6). This correlation was consistent with previous literatures: crystallinity has 
shown to be correlated with Young’s modulus at microscale;(32) moreover, Young’s 
modulus has shown to be correlated with whole bone strength at macroscale.(33) 
Furthermore, crystallinity and fracture toughness explained 63% of the variations in 
whole bone bending strength. This correlation showed that fracture toughness not only 
independently contributed to bone failure, but also contributed to bending strength to 
some degree; hence, two of the three distinct material properties that describe bone 
failure were related to each other in the present study (Figure 2.6).  
Fatigue life, on the other hand, was not correlated with either fracture 
toughness or strength (Figure 2.5). Measurements from fatigue testing were sensitive 
to local microstructural details. In bone, cement line and other heterogeneities may 
limit the propagation of small cracks initiated by fatigue loading, resulting more 
variations in fatigue life. Fracture toughness and strength, on the other hand, are less 
dependent on random flaws or tissue heterogeneity. Due to the larger variations in 
fatigue behavior and small sample size, important correlations between whole-bone 
strength, fracture toughness and fatigue properties were not detected.  
We attributed differences in tissue fracture toughness in PTH-treated bone 
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primarily to changes in osteon number and geometry. Clinically and in animal 
models,(34,35) PTH elevates the turnover rate; thereby increasing the number of osteons 
(Figure 2.1). Fracture toughness has been positively correlated with larger numbers of 
small osteons;(19) however, although PTH increased osteon density, the size of the 
osteons and Haversian canals were larger in the PTH-treated group. Larger osteons 
contribute to larger osteonal area (including Haversian canals), resulting increased 
porosity which negatively correlates to fracture toughness.(19) Therefore, we attribute 
the reduction in fracture toughness to larger Haversian canals and associated porosity 
from increased turnover in the PTH-treated group.  
The mineral-to-matrix ratio in the osteons increased with tissue age and was 
elevated in the PTH-treated group whereas both indentation modulus and hardness 
were not different with tissue age and were decreased with PTH treatment. 
Mineralization is known to increase with tissue age,(36,37) consistent with our findings. 
However, the elevated mineralization with PTH treatment was not consistent with 
previous studies. Clinically, PTH treatment decreased mineralization and crystallinity 
measured by FTIR in osteoporotic patients.(38) Mineralization showed positive 
relationship with indentation modulus and hardness.(15) The absence of the positive 
relationship in our study might be resulted from the narrower range of indentation 
modulus and mineralization. In bamboo models,(15) indentation modulus ranged from 
24-38 GPa and mineralization was from 5-10 whereas in the present study, indentation 
modulus ranged from 24-31 GPa and mineralization was from 6-8, demonstrating the 
negative relationship with mineralization. If more measurements across the entire 
cortex were obtained, positive relationship between indentation modulus and 
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mineralization would be captured. Moreover, we did not see a relationship between 
nanoindentation parameters and tissue age. A limitation of our tissue age data is our 
inability to know whether the specific osteons examined were recently formed or fully 
mineralized at the time of analysis. Alternatively, we might not have characterized the 
newly-formed bone tissue. We labeled our animals with tetracycline but did not 
measure turnover rate due to technical errors in dosage of formation markers. We do 
not know whether turnover in the femur increased with PTH treatment.   
Combined OVX and MA diet was selected to produce extreme osteopenia, 
which is an appropriate model for post-menopausal osteoporosis. In the sheep, OVX 
induces increased bone resorption for six months, which was indicative of a high bone 
turnover rate and leads to bone loss in the vertebrae.(39) In sheep, dietary-induced MA 
reduced bone mineral density compared to sham surgery.(40) After 12 months, BMD in 
ovariectomized sheep in our study was consistent with other studies (data not 
shown).(41)  
As in any experiment, certain limitations exist. We chose to use the femur for 
these analyses, as the femur is the most appropriate site for whole bone mechanical 
tests. However, reviewing the literature we found reports that ovariectomized sheep of 
comparable age to ours showed less loss of BMD in the femur than at other skeletal 
sites.(42,43) Bone volume fraction changed before and after PTH treatment in the spine, 
which are dominantly consisted of cancellous bone, of our animals (data not shown). 
The spine could have macroscopic and nanoscale differences with PTH treatment. 
Another consideration is the optimum dosage, duration, and frequency of the PTH 
treatment. We used the dose recommended for sheep.(44) The absence of hypercalcemia 
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which resulted from over-dose of PTH treatment(45) in the sheep indicates the PTH 
dosage was appropriate. Previously, a monkey model was also treated with teriparatide 
(1-34) 5µg/kg/day for 12 months.(46) In the clinical trial, patients were subcutaneously 
injected with parathyroid hormone (1-34) 20 or 40 µg daily for 21 months.(47) 
However, the effective treatment time period for sheep are unknown and one year of 
treatment may not be sufficient to observe an effect. In the present study, most serum 
measures (CTx, BAP, ALP, and Ca) demonstrated maximum changes at 20 rather than 
24 months, suggesting that by 24 months, whole body markers of bone turnover might 
return to steady state. Furthermore, because few tetracycline double labels were 
apparent, new bone formation at the end of the experiment appeared to be minimal 
compared to other ovariectomized models.  
Finally, we did not include sham-operated animals. In the present study, a 
sham-operated group might demonstrate whether bone loss from ovariectomized and 
metabolic acidosis was sufficient in the Vehicle group. Additionally, a drug holiday, 
stopping the treatment for a period of time, or combining different categories of 
treatment, could also be considered.(48) Monkey models with PTH treatment for 12 
months followed by 6 months withdrawal still preserved the strength increase at the 
proximal femur compared to the OVX group; and the strength was not different from 
18 months continuous treatment.(46) Rodent models treated with PTH for the first 8 
weeks followed by bisphosphonate for 8 weeks prevented the decrease in mechanical 
strength that occurred after an 8-week PTH-withdrawal.(49)    
 In summary, few studies have examined the alteration of tissue mechanical and 
compositional properties after PTH treatment using animal models with Haversian 
  58 
remodeling.(12,14) The significance of this study was to evaluate treatment and tissue 
age effects on mechanical properties and composition across different length-scales, 
from macro- to nano-scale. In addition, this study is the first to correlate all three 
tissue properties, whole bone strength, fracture toughness and fatigue behavior, that 
describe mechanical failure of bone together. We saw differences in the nanoscale 
composition and tissue mechanical properties with PTH treatment. Although we did 
not see variations in whole bone strength between treatment groups, alterations in 
tissue properties with PTH were critical contributors to fatigue properties and fracture 
toughness (crack propagation resistance). For example, whole bone bending strength 
can be explained by tissue composition and fracture toughness. In addition to the 
effects of PTH treatment on cortical bone in the current study, several studies have 
shown a response at cancellous sites,(47,50) the alteration of mechanical and material 
properties in the cancellous bone is under investigation.  
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CHAPTER 3 
PARATHYROID HORMONE (PTH) IMPROVES BONE HETEROGENEITY 
AND PRESERVES MECHANICAL PROPERTIES OF CANCELLOUS BONE 
BEFORE FATIGUE FAILURE IN A SHEEP MODEL OF OSTEOPOROSIS* 
 
 
3.1   Introduction 
 
Osteoporosis is a multifaceted condition characterized by loss of bone quantity 
and a deterioration of bone tissue quality, both contributing to fragility fractures. 
Typical osteoporotic fractures, at the hip for example, are due to a single overload.(1) 
Not all osteoporosis-related fractures, however, are caused by the application of a high 
load. Most loading during daily activities occurs at levels well below failure loads. 
Over time, these repetitive loads can lead to failure, particularly at sites such as the 
vertebra. By investigating the alterations in fatigue properties caused by osteoporosis 
and osteoporosis treatments, we can better understand bone fragility.  
Osteoporotic fractures mainly occur at the spine, hip and wrist,(2) sites that 
contain large volumes of cancellous bone. The complex architecture of cancellous 
bone can be characterized as rod- and plate-type structures.(3) The contribution of each 
type of trabecula to the mechanical properties of the whole tissue has been examined 
through microCT images and finite element simulations.(4) When a single compressive 
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load to 1% strain was simulated, rod-like trabeculae failed early while plate-type 
trabeculae failed after yielding. Plate-shaped trabeculae, primary aligning with loading 
direction, are important to withstand single compressive loading whereas rod-type 
trabeculae are critical to stabilize the whole structure and to initiate failure.(4)  
Besides tissue architecture, tissue mechanical and material properties are also 
important contributors to fracture risk. Local variations in tissue properties result from 
remodeling. Mineral and matrix constituents vary within each trabecula as a result of 
bone turnover initiated on the surface.(5-7) Heterogeneity of the mineralized tissue is 
decreased by osteoporosis and bisphosphonate treatment.(8,9) The loss of heterogeneity, 
with a corresponding increase of microcracks in the tissue, is thought to decrease 
mechanical strength and facilitate crack propagation.(10) Lower indentation modulus 
and mineralization near surfaces of trabeculae were measured with anti-resorptive 
treatment in a sheep model.(11) Therefore, both alterations of microarchitecture and 
tissue properties of osteoporotic and treated cancellous tissue should be examined to 
fully understand bone fracture.  
Intermittent parathyroid hormone (iPTH) is an FDA-approved anabolic 
osteoporosis treatment that prolongs the life span of osteoblasts and stimulates bone 
formation.(12-14) Clinically, PTH decreases fracture risk of the spine by 10%.(15) 
Cancellous bone volume increases with PTH treatment and trabecular numbers and 
thickness are elevated clinically and in animal models.(16-20) Moreover, PTH increases 
bone strength at the femoral neck and vertebra in ovariectomized rat models.(21,22) 
However, its effect on bone tissue composition and mechanics in larger animals is 
unknown, particularly under cyclic fatigue loading. 
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The main goal of this study was to determine the effect of PTH on material and 
mechanical properties of cancellous bone at both the micro- and nanoscale using a 
sheep model of osteoporosis. Additionally, we examined the correlation between the 
alterations in architecture and composition, and mechanical properties. Our hypothesis 
was that PTH would improve measures of bone quality, such as tissue heterogeneity, 
and preserve mechanical properties during cyclic fatigue loading through architectural 
and compositional changes relative to osteopenic ewes.  
 
3.2   Methods 
 
3.2.1   Animal model 
 
 Under an IACUC-approved protocol at the University of Minnesota 
(#0907A68881) and Hospital for Special Surgery (#11-09-02E), thirteen mature Swiss 
Ramboulet female ewes (6-7 years old, weighing 69-82 kg at the start of the 
experiment) were ovariectomized and fed a metabolic acidosis (MA) diet for one 
year.(11) All ewes were then remained on the MA diet, and seven sheep were 
randomized into the parathyroid hormone treatment group (teriparatide 1-34, 
generously provided by Eli Lilly, 5µg/kg/day subcutaneous injection, PTH group, n = 
7) and the remaining six sheep received saline injections (Vehicle group, n = 6) for the 
following one year.  
Ewes were weighed monthly and subjected to bone density measurements at the 
onset (0 month), one year after ovariectomy (13 month), and terminus of the experiment 
(24 month) (General Electric Lunar DEXA machine, Madison, Wisconsin, USA). 
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Quarterly serum analysis of PTH, calcium, CTx, NTx and vitamin D was provided over 
2 years. One year after treatment with either PTH or saline, the ewes were euthanized. 
Sheep were given tetracycline injections 18 and 9 days before euthanasia for analysis 
of mineral apposition rate (MAR, µm/day). Cancellous tissue characterization was 
performed on two cores and one section from the distal end of the right femur, one core 
from the L6 vertebrae, and two biopsies from the iliac crest taken at 13 and 24 months.  
 
3.2.2   MicroCT (2 femoral cores, 1 vertebral core, 2 iliac crest biopsies per sheep) 
 
Cancellous bone architecture of all femoral and vertebral cores and iliac crest 
biopsies was examined by microCT. (12 µm voxel size, Micro-CT35, Scanco Medical 
AG, Brüttiselen, Switzerland or 25 µm voxel size, eXplore CT 120, GE Healthcare, 
Waukesha, WI, USA). Trabecular bone volume fraction (BV/TV), trabecular number 
(Tb.N), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), tissue mineral 
density (TMD) and connectivity density (Conn.D) were measured.  
 
3.2.3   Individual trabeculae segmentation (ITS) (2 femoral cores and 1 vertebral 
core per sheep) 
 
 Cancellous morphology of the femoral and vertebral cores was evaluated using 
individual trabeculae segmentation (ITS). MicroCT images were segmented to 
identify individual plates and rods.(3) Number, volume fraction, and mean 
thickness/diameter were determined for rod- (rN, rBV/TV, rTb.Th) and plate-like 
trabeculae (pN, pBV/TV, pTb.Th). Orientations of each type were characterized as 
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longitudinal (0° ≤ F ≤ 30°), oblique (30° < F ≤ 60°), and transverse (60° < F ≤ 90°). 
Volume fraction for each orientation within the type was also calculated. 
 
3.2.4   Bulk cancellous tissue preparation (2 femoral cores per sheep) 
 
 Tissue architecture and mechanical properties were characterized in femoral 
cores (n = 2/sheep). Bulk samples were visually aligned in the principal stress 
directions(23) (Faxitron, Hewlett Packard, McMinnville, Oregon, USA) prior to 
removing cancellous cores (7.5 mm). Both ends of each specimen were glued (Loctite 
406, Newington, CT, USA) into customized press-fit brass end-caps(24). The average 
original length, exposed length and diameter of the core were measured for stress and 
strain calculation.  
 
3.2.5   Monotonic compression and ashing (1 femoral core per sheep) 
 
 Bulk tissue properties were characterized by monotonic compression on a 
single femoral core. Preconditioning was completed by 5 cycles of 0 to 0.1% 
compressive strain. After preconditioning, monotonic loading was applied until 2.5% 
strain (858 Mini Bionix, MTS, Eden Prairie, MN, USA). Young’s modulus, yield 
strength and ultimate strength were determined. After monotonic loading, cores were 
cut from the end caps and ashed at 600 ˚C for 18 hours. Ash fraction was calculated as 
ash weight/dry bone weight.(25)  
 
3.2.6   Cyclic fatigue tests and damage staining (1 femoral core per sheep) 
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 Using the second femoral core, fatigue behavior was determined by cyclic 
compressive loading (Bose Electroforce LM-1, Eden Prairie, Minnesota, USA). 
Preconditioning from 0%-0.1% strain was applied to calculate the initial modulus (E0) 
and the force corresponding to a normalized stress (s/E0) of 0.004 mm/mm. Samples 
were loaded in force control between 0 N and the desired force at 4Hz using a 
haversine waveform until 2.5% strain. All testing was conducted at physiologic 
temperature (37˚C) in hydroxyapatite-buffered PBS. Cycles-to-failure (Nf), percent 
change of secant modulus (E/E0 -1), and energy dissipation (U, kJ/m3) were 
determined. Following fatigue loading, damage volume fraction (DV/BV) was 
determined with lead uranyl acetate (LUA).(26,27)   
 
3.2.7   Tissue preparation (1 femoral section, 1 vertebral core and 2 iliac crest 
biopsies per sheep) 
 
Nanoscale composition and nanomechanical properties of cancellous tissue 
from the femur, vertebra and iliac crest were characterized using nanoindentation, 
Raman spectroscopy, Fourier transform infra-red spectroscopy Imaging (FTIRI) and 
AFM-IR. Tissue samples were embedded in PMMA. For nanoindentation and Raman 
spectroscopy, a 3-mm slice was cut from the embedded distal femur and polished 
anhydrously.(28) For FTIRI, 1-2 µm thick sections were cut from the embedded iliac 
crest biopsies and vertebral core (Leica SM 2500 tissue microtome). For AFM-IR, 300 
nm thick sections were cut from the embedded vertebral core (Reichert-Jung Ultracut 
E ultramicrotome, Vienna, Austria).  
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3.2.8   Nanoindentation (1 femoral section per sheep) 
 
 Tissue nanomechanical properties were determined using nanoindentation. 
Indents were made with a Berkovich diamond indenter in three selected trabeculae, 
resulting in 30-45 indentations per animal (TriboIndenter, Hyistron Inc., Minneapolis, 
MN).(11) The load function included a 10 second hold at 700 µN with 
loading/unloading at a rate of 50 µN/s, resulting in ~150 nm indentation depth. The 
indentation modulus (Ei) and hardness (H) were calculated from the unloading part of 
the load-displacement curve.(11,28,29)  
 
3.2.9   Raman Spectroscopy (1 femoral section per sheep) 
 
 Nanoscale tissue composition was evaluated with Raman spectroscopy (InVia 
microRaman, Renishaw, Gloucestershire, United Kingdom).(30). A 2 µm2 laser spot 
was centered at the same mid-lamellar locations probed by nanoindentation. Spectra 
were collected between 800 and 1800 cm-1 with background fluorescence removed 
using WiRETM V4.1 software (Reinshaw). Outcomes included tissue mineralization 
(mineral:matrix), B-type carbonate substitution (carbonate:phosphate), and 
crystallinity.(30) 
 
3.2.10   FTIRI (1 vertebral core and 2 iliac crest biopsies per sheep) 
 
FTIRI spectra of vertebra and iliac crest specimens were collected, baselined 
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and analyzed as detailed elsewhere(31) (Spectrum 300 Imaging System, Perkin Elmer 
CT, USA; Isys 5 software, Spectral Dimensions, MD USA). Outcomes included 
mineral-to-matrix ratio (M/M), carbonate substitution (CO3/PO4), crystallinity (XST), 
acid phosphate substitution ratio (HPO4) and collagen crosslink ratio (XLR).(31)  In 
addition to mean values, heterogeneity was determined from the pixel distributions for 
each parameter.(9)  
 
3.2.11   AFM-IR (1 vertebral core per sheep) 
 
Three trabeculae per sample were analyzed by AFM-IR (nano-IR2TM Anasys 
Instruments, Santa Barbara, CA). Data were acquired in contact mode using an Arrow 
cantilever (Anasys Instrument model PR-EX-nIR2-10). Images were collected at 6 
different wavenumbers (1030 cm-1, 1660 cm-1, 1020 cm-1, 1690 cm-1, 1128 cm-1, 1096 
cm-1) and analyzed at 50-100 nm spatial resolution (Analysis Studio software, Anasys 
Instruments, Santa Barbara, CA). All spectra were collected over a range of 900–1800 
cm-1 at 4 cm-1 spectral resolution, then smoothed using a Savitzky-Golay filter and 
baselined (MATLAB, Mathworks®, Massachusetts, U.S.A). Outcomes included 
mineral:matrix ratio, crystallinity, collagen crosslink ratio, and acid phosphate 
substitution ratio.(32) 
 
3.2.12   Data analysis 
 
 PTH-treatment effects on serum markers, microCT, ITS, mechanical testing 
and AFM-IR measurements were analyzed with Student’s t-test (JMP 11.0, SAS 
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Institute, INC.). Data collected from nanoindentation and Raman spectroscopy were 
classified into three groups (11): Superficial (< 20 µm away from trabecular edge), 
Intermediate (20-40 µm away from trabecular edge) and Central (> 40 µm from 
trabecular edge). Repeated nested ANOVA or generalized estimating equations (GEE) 
determined the effects of PTH treatment and tissue age on cancellous tissue properties 
from nanoindentation, Raman spectroscopy and FTIR. Regression analysis was 
performed with averaged values to determine the contribution of composition and 
microarchitecture to mechanical properties. Significance level was p < 0.05.  
 
3.3   Results 
 
3.3.1   Animal model 
 
Vehicle group gained weight gradually throughout 24 months (Table 3.1). PTH-
treated ewes, however, failed to gain weight during 24 months and weighted less than 
Vehicle group. At the onset of treatment, PTH level in the treated ewes rapidly 
increased, reached a plateau and remained at that level. Despite these increases in PTH 
level, calcium level remained steadfast (1.08±0.18 mg/l in Vehicle and 1.060±0.11 mg/l 
in PTH). Vitamin D level was comparable until month 20 (69±7 nmoles/L in Vehicle 
and 63±10 nmoles/L in PTH). 24 months following ovariectomy, vitamin D level in the 
PTH-treated ewes (61.14 ±18.67 nmoles/L) was at a significantly lower level than that 
in the Vehicle group (84.50 ±10.74 nmoles/L, p = 0.012, Table 1). CTx and NTx 
turnover markers did not vary throughout the study (Table 3.1). At 17 month, however, 
CTx in the PTH-treated ewes was greater than that in Vehicle. The bone mineral density 
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in vertebra from Vehicle group, determined by DEXA, was significantly lower at 0 
month (Table 3.1). PTH maintained BMD after 1 year of treatment whereas BMD 
decreased in Vehicle group at 24 month compared to 13 month. Mineral apposition rate 
(MAR) in spine from Vehicle group was not lower (1.538 ± 0.06 µm/day) than that from 
PTH group (1.622 ± 0.23 µm/day). 
 
Table 3.1 Sheep body weight was lower with PTH treatment. Bone mineral density   
                 was maintained by PTH treatment whereas BMD had a trend towards  
                 decreasing in Vehicle group. Vitamin D was decreased at 24 months in  
                 PTH-treated group. Changes in serum CTx had a trend towards increasing  
                 with PTH treatment. Serum PTH at 24 months was higher in the PTH  
                 treatment group. 
                 Data shown as mean (SD). *p < 0.05. **p < 0.1. +compared the difference  
                 between 24 mo. to 13 mo. with treatment effect (p < 0.1). 
 
 Onset (ovariectomy) 
(0 mo.) 
1 year after ovariectomy 
(13 mo.) 
1 year after treatment 
(24 mo.) 
 Vehicle PTH Vehicle PTH Vehicle PTH 
Sheep characteristics   
   Body weight  
                    (lb) 
163.3 (7.7) 165.3 (8.3) 185.8 (8.0) 166.4 (11.8)* 185.5 (11.4) 157.9 (20.1)* 
  BMD  (g/cm2) 1.19 (0.15) 1.36 (0.18)* 1.28 (0.18) 1.21 (0.13) 1.16 (0.20)+ 1.16 (0.22) 
Serum markers   
  Calcium  
              (mg/L) 
1.11 (0.07) 1.03 (0.04) 0.74 (0.27) 0.89 (0.27) 1.20 (0.11) 1.12 (0.05) 
  Vitamin D  
        (nmolel/L) 
76.17 (12.9) 71.83 (19.9) 61.00 (19.9) 50.43 (15.6) 84.5 (11.8) 61.14 (20.2)* 
  CTx   (ng/mL) 0.56 (0.3) 0.59 (0.2) 0.41 (0.2) 0.64 (0.5)** 0.18 (0.1) 0.86 (1.6)** 
  NTx  51.16 (20.6) 49.72 (25.8) 43.17 (30.4) 41.81 (13.4) 57.01 (22.6) 51.27 (28.9) 
  PTH (pmol/L) 0.05 (0.12) 0.03 (0.08) 0.22 (0.17) 0.11 (0.15) 0.05 (0.12) 0.31 (0.18)* 
 
 
3.3.2   MicroCT (2 femoral cores, 1 vertebral core, 2 iliac crest biopsies per sheep) 
 
MicroCT analysis for femoral cores (Table 3.2) had lower Tb.Sp and higher 
Connn.D in PTH group compared to Vehicle group. Other parameters were not 
different. In the vertebra no significant differences were noted. In iliac crest biopsies, 
  75 
PTH maintained most parameters. BV/TV in the PTH group had a trend towards 
experiencing 35% less bone loss compared to the Vehicle group (p < 0.1). Compared to 
baseline, PTH treatment prevented a significant decrease in Tb.Th compared to the 
Vehicle group in iliac crest.  
 
Table 3.2 Loss of bone volume fraction from the cancellous site at iliac crest had a  
                 trend towards maintaining by PTH treatment. Trabecular number (Tb.N)  
                 was higher and trabecular separation (Tb.Sp) decreased with PTH  
                 treatment in femur. Data shown as mean (SD). *p < 0.05. **p < 0.1 
                         aSignificant increase compared to baseline.   
                         bSignificant decrease compared to baseline 
 
 Vehicle Group PTH Group 
Iliac crest  
 Bone volume fraction (BV/TV) 0.14 (0.01)b 0.19 (0.03)**b 
 Tissue mineral density (TMD) 594.77 (21.92) 704.8 (16.90) 
 Trabecular thickness (Tb.Th) 0.10 (0.01)b 0.13 (0.03) 
 Trabecular separation (Tb.Sp) 0.56 (0.06)a 0.67 (0.06)a 
 Trabecular number (Tb.N) 1.30 (0.14)b 1.50 (0.15)b 
Vertebra  
 Bone volume fraction (BV/TV) 0.28 (0.02) 0.36 (0.20) 
 Tissue mineral density (TMD) 848.97 (30.31) 870.53 (35.25) 
 Trabecular thickness (Tb.Th) 0.13 (0.01) 0.15 (0.04) 
 Trabecular separation (Tb.Sp) 0.43 (0.06) 0.42 (0.14) 
 Trabecular number (Tb.N) 2.71 (0.50) 3.12 (1.67) 
Femur  
 Bone volume fraction (BV/TV) 0.25 (0.06) 0.22 (0.05) 
 Trabecular thickness (Tb.Th) 198.3 (23.03) 199.9 (18.90) 
 Trabecular separation (Tb.Sp) 6.20 (1.90) 4.29 (1.30)* 
 Trabecular number (Tb.N) 1.05 (0.40) 1.39 (0.80)* 
 
3.3.3   Individual trabeculae segmentation (ITS) (2 femoral cores and 1 vertebral 
core per sheep) 
 
Microstructure differed among regions of the skeleton (Table 3.3). In femoral 
cores, rN and rBV/TV were 12.5% and 52.0% greater with PTH treatment compared to 
the Vehicle group. rBV/TV in longitudinal, transverse, and oblique orientations were 
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all increased by 144.4%, 55.6%, and 32.8% (p < 0.1) in the PTH group relative to 
Vehicle group. pBV/TV declined by 5.8% with PTH treatment; specifically, pBV/TV 
in longitudinal orientation had a trend towards decreasing 10.1% (p < 0.1). pTb.Th and 
rTb.Th were not different between two groups. In the vertebra, rTb.Th was lower and 
pBV/TV in the oblique direction was higher in the PTH-treated group. There were 
trends for a lower pBV/TV in longitudinal direction, a higher pBV/TV in transverse 
direction and a higher pTb.Th in the PTH-treated group. 
Table 3.3 PTH treatment has anatomic-dependent effects. In femur, number and volume  
                fraction of rods were increased with PTH treatment whereas in vertebrae,  
                mean plate-shaped trabecular thickness was increased with PTH treatment.           
                Data shown as mean (SD). *p < 0.05. **p < 0.1 
 
 Femur Vertebra 
 Vehicle Group PTH Group Vehicle Group PTH Group 
Number of plates (pN, 
1/mm) 
3.74 (0.20) 3.90 (0.51) 3.44 (0.23) 3.23 (0.36) 
Number of rods (rN, 1/mm) 2.56 (0.25) 2.88 (0.37)* 2.01 (0.19) 2.01 (0.29) 
Volume fraction of plates 
(pBV/TV) 
0.898 (0.04) 0.846 (0.05)* 0.971 (0.007) 0.975 (0.011) 
 
Volume fraction of rods 
(rBV/TV) 
0.102 (0.03) 0.155 (0.05)* 0.031 (0.006) 0.028 (0.01) 
pBV/TV in longitudinal 
orientation 
0.666 (0.07) 0.599 (0.08)** 0.87 (0.03) 0.85 (0.04)** 
pBV/TV in transverse 
orientation 
0.058 (0.01) 0.065 (0.02) 0.028 (0.008) 0.034 
(0.01)** 
pBV/TV in oblique 
orientation 
0.174 (0.03) 0.183 (0.05) 0.074 (0.01) 0.095 (0.03)* 
rBV/TV in longitudinal 
orientation 
0.009 (0.004) 0.022 (0.013)* 0.003 (0.0007) 0.003 (0.001) 
rBV/TV in transverse 
orientation 
0.036 (0.01) 0.056 (0.02)* 0.02 (0.004) 0.02 (0.006) 
rBV/TV in oblique 
orientation 
0.058 (0.02) 0.077 (0.02)** 0.008 (0.002) 0.008 (0.003) 
Mean plate-shaped 
trabecular thickness 
(pTb.Th, µm) 
150.4 (16.6) 153.9 (28.4) 150.8 (6.4) 166.9 (21.7)* 
Mean rod-shaped trabecular 
diameter (rTb.Th, µm) 
129.4 (9.91) 132.7 (10.7) 106.8 (6.05) 100.4 (6.32)* 
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3.3.4   Mechanical tests at bulk and tissue-level (2 femoral cores and 1 femoral 
section per sheep) 
 
The effect of PTH treatment was evident in the resistance to fatigue loading 
but not for monotonic loading. Young’s modulus, yield stress/strain, ultimate 
stress/strain, total toughness to ultimate, and ash fraction from monotonic compression 
were not different among groups (Table 3.4). E0, Nf, and DV/BV from cyclic fatigue 
loading were not different between two groups (Table 3.4). However, reduction in 
modulus and energy dissipation were maintained with PTH treatment relative to the 
Vehicle group before fatigue failure (Figure 3.1). Additionally, Ei was 10.7% greater 
at Central and 11.6% greater at Intermediate with PTH treatment (Figure 3.2). H was 
not different with PTH treatment (Figure 3.2).  
 
Table 3.4 No treatment effect with monotonic compression strength and fatigue life  
                 compared to Vehicle group.  
 
 Vehicle Group PTH Group 
Monotonic compression loading 
  Young’s modulus (MPa) 662.6 (312) 839.3 (374) 
  Yield stress (MPa) 4.15 (1.6) 4.96 (2.1) 
  Yield strain (%) 0.86 (0.2) 0.80 (0.1) 
  Ultimate stress (MPa) 5.38 (1.7) 5.91 (1.9) 
  Ultimate strain (%) 2.32 (0.86) 1.75 (0.66) 
  Total toughness to ultimate (kJ/m3) 91.15 (44.0) 70.24 (20.1) 
  Ash fraction (%) 66.87 (8.91) 61.51 (11.9) 
Cyclic fatigue loading 
  Failure cycles (Nf, 106 cycles) 0.81 (1.4) 1.77 (2.7) 
  Initial modulus (E0, MPa) 477.1 (212) 516.1 (122) 
  Damage fraction (DV/BV, %) 8.7 (6) 9.3 (6) 
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A         
B         
Figure 3.1 PTH (A) maintained modulus and (B) experienced less energy dissipation  
                  during fatigue loading vs. Vehicle. Data shown as fraction of total fatigue  
                  life (0-100%).  PTH = red lines; Vehicle = blue lines. 
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Figure 3.2 (A) Indentation modulus (Ei) in Intermediate and Central increased with  
                   PTH treatment. (B) No treatment effect with hardness (H). (C)  
                   Mineralization in Central and Intermediate declined in PTH group. (D)  
                   Crystallinity was not affected by PTH treatment.  
                   Blue empty bar indicated Vehicle group. Red solid bar indicated PTH  
                   group. †different from Vehicle group for the region indicated; *different  
                   from Superficial within the indicated group. 
 
3.3.5   Raman (1 femoral section per sheep) 
 
Mineralization declined by 18.3% within Central and by 11.5% within 
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Intermediate with PTH treatment compared to the Vehicle group (Figure 3.2). 
Mineralization was higher in Central and Intermediate compared to Superficial zone. 
B-type carbonate substitution and crystallinity were not affected by PTH treatment 
(Figure 3.2).  
 
3.3.6   Regression Analysis 
 
Correlations between composition, microarchitecture and mechanical properties 
were examined. rBV/TV explained 50% of the variation in energy dissipation. pBV/TV 
in oblique orientation explained 57% of the variation in Nf while pBV/TV in 
longitudinal direction explained 60% of the variation of Eo. In addition, 77% of the 
variation in energy dissipation was explained by rBV/TV and mineralization (Table 
3.5).  
  
Table 3.5 Correlations between microarchitecture, composition and mechanical  
                 properties. 77% of the variation in energy dissipation was explained by  
                 volume fraction of rods and mineralization. Shaded rows indicated more  
                 than one independent variables in the regression model. *p < 0.05. 
 
Predictor Response (Independent Variables) Adjusted R2 
Energy dissipation Volume fraction of rods (rBV/TV) 0.40* 
Energy dissipation Mineralization (Superficial) 0.14 
Energy dissipation rBV/TV, Mineralization (Superficial) 0.77* 
Fatigue life Volume fraction of plates in transverse orientation 0.50* 
Fatigue life Volume fraction of plates in oblique orientation 0.57* 
Initial modulus Volume fraction of plates in longitudinal orientation 0.60* 
 
 
3.3.7   FTIRI (1 vertebral core and 2 iliac crest biopsies per sheep) 
 
Vertebral core at 24 month had no significant difference in means between two 
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groups (Table 3.6). Collagen crosslink ratio had a trend towards a decrease with PTH 
treatment. PTH treatment prevented the loss in crystallinity associated with ovariectomy 
and metabolic acidosis in iliac crest. Moreover, PTH treatment improved two 
parameters, carbonate-to-phosphate ratio decreased and acid phosphate substitution 
ratio increased relative to baseline.  
The distribution of pixel intensities was characterized in terms of the line-width 
at half-maximum of the pixel histogram for each image. The averages of these 
heterogeneities (Table 3.6) showed that mineral-to-matrix heterogeneity was 
maintained and carbonate-to-phosphate heterogeneity was increased by PTH treatment 
compared to baseline in iliac crest. PTH treatment also prevented the loss in crystallinity 
heterogeneity; however, unexpectedly the carbonate-to-phosphate heterogeneity was 
also increased in the Vehicle group compared to baseline. None of the other variables 
were different from the Vehicle group because of the large scatter in the data. 
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Table 3.6 FTIR mean and heterogeneity results in the iliac crest and vertebra. In the  
                 vertebra, there is no significant difference between Vehicle and PTH groups.  
                 In the iliac crest, the ovariectomized animals had higher crystallinity  
                 compared to baseline. PTH decreased the carbonate-to-phosphate ratio and  
                 increased the acid-phosphate-substitution ratio and the crystallinity  
                 heterogeneity compared to baseline.  
                          avehicle is significantly different from baseline p<0.05 
                          bPTH is significantly different from baseline p<0.05 
                 *Vehicle is significantly different from PTH at completion p<0.05. ** p<0.1 
 
 
 Iliac crest Vertebra 
 Baseline Vehicle PTH Vehicle PTH 
Mean      
M/M 4.245±0.583 4.232±0.409 4.219±0.348 4.707±0.269 4.883±0.294 
CO3/PO4x103 8.367±0.675b 8.100±1.010 7.286±1.074b 7.443±0.963 7.381±0.419 
XST 1.180±0.020a 1.203±0.018a 1.193±0.030* 1.239 ±0.023 1.215±0.060 
HPO4 0.472±0.043b 0.476±0.032 0.496±0.040b 0.384±0.027 0.394±0.014 
XLR 3.794±0.282 4.384±0.590 4.189±0.583 3.870±0.369 3.586±0.288** 
Heterogeneity  
M/M 0.951±0.123a 0.833±0.182a 1.030±0.147 1.505±0.099 1.632±0.288 
CO3/PO4x103 2.276±0.366a,b 2.679±0.553a 2.473±0.333b 2.678±0.163 2.995±0.053 
XST 0.069±0.009a,b 0.067±0.011a 0.068±0.010b 0.139±0.015 0.135±0.028 
HPO4 0.062±0.017 0.082±0.027 0.067±0.012 0.104±0.011 0.111±0.022 
XLR 0.350±0.090 0.346±0.078 0.360±0.131 0.490±0.104 0.421±0.081 
 
 
3.3.8   AFM-IR (1 vertebral core per sheep) 
 
To characterize the least-mature bone tissue, AFM-IR were performed on the 
tissue between double fluorescent labels. In this newly-formed bone tissue (superficial 
zone), higher mineral content, higher collagen content and collagen maturity were 
captured by line scans in PTH group compared to Vehicle group (Figure 3.3). In 
addition, PTH group had higher mineral-to-matrix ratio, crystallinity and collagen 
crosslink ratio and lower acid phosphate substitution ratio in IR images (Figure 3.4), 
indicating a faster maturation process. In the more-mature bone tissue (central zone) 
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(Figure 3.4), the mineral-to-matrix ratio and the acid phosphate substitution ratio were 
lower in the PTH group compared to Vehicle group.  
Both groups presented variations with bone maturity. Mineral-to-matrix ratio 
increased with bone maturity, due to an increase in mineral content and a decrease in 
collagen content, whereas the acid phosphate substitution ratio decreased with bone 
maturity. The IR images also showed the same variations of IR parameters with bone 
maturity (Figure 3.4).  
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Figure 3.3 AFM-IR parameters for the PTH group (red) compared to the Vehicle  
                  group (blue) as a function of distance from the trabecula edge, increasing  
                  distance representing more mature bone. The first 20 microns are  
                  considered as newly formed bone. In the newly formed bone, the bone  
                   formation process is accelerated when samples are treated with PTH. In the  
                  more mature bone, the bone formed with PTH has a lower mineral-to-matrix  
                  ratio and a lower acid-phosphate-substitution ratio. Green dot represented  
                  both groups are significantly different, yellow dot represented a trend. 
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Figure 3.4 AFM-IR images for one sample from the Vehicle group (top) and from the  
                  PTH group (bottom). In the first 20 microns from the trabecular edge, the  
                  PTH group shows higher mineral-to-matrix ratio, crystallinity and  
                  collagen crosslink ratio and lower acid phosphate substitution ratio,  
                  suggesting that the bone formation process is accelerated with PTH  
                  treatment.  
 
3.4   Discussion 
 
PTH treatment is an FDA-approved anabolic agent for osteoporosis, stimulating 
bone formation in OVX animals(33) and in postmenopausal women;(34) thus potentially 
avoids the detrimental decrease in heterogeneity encountered with antiresorptive 
agents,(35) maintaining the mechanical integrity of bone.(36) Therefore, in the present 
study, we investigated the effect of intermittent PTH treatment on the mechanical 
properties and tissue heterogeneity in an osteopenia ovine model at several bone sites 
with microCT, histology, mechanical testing, nanoindentation, Raman, FTIR and AFM-
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IR. We were able to verify our hypothesis that PTH treatment improved tissue 
heterogeneity and preserved the fatigue properties through increased rod-type 
trabeculae and tissue compositional changes.  
PTH-treated sheep gained less weight, analogous to PTH-treated humans 
showing a weight loss, attributing to mild hypercalcemia reducing apatite.(37) However, 
hypercalcemia and altered vitamin D levels were not noted in these sheep. These sheep 
might be more active due to their improved health status. The metabolic acidosis diet 
can result in reduced muscle function correcting by a slight elevation in calcium level 
during PTH treatment. The paucity of labels in these samples was our failure to provide 
the tetracycline for multiple days prior to biopsy. Previous study(38) first injected 
tetracycline for two days before a 12-day break and a second injection for 14 days in 
PTH-treated sheep, showing a significant anabolic effect.   
The ovariectomized ewe with metabolic acidosis had distinct changes at 
different bone sites.(39) Microarchitecture parameters measured by microCT were more 
altered in femur and iliac crest compared to vertebra, confirming a site-dependent effect 
of PTH. No significant difference was found in vertebra whereas Tb.N was higher and 
Tb.Sp was lower with PTH treatment in the femur. BV/TV was altered in iliac crest in 
PTH group compared to the Vehicle group (Table 2), consistent with new bone 
formation. Tb.Th and Tb.N were maintained with PTH treatment. Iida-Klein et al.(40) 
found a more robust response to PTH treatment in mice long bone relative to spine 
whereas the spine seemed to respond first in human. Moreover, as hypothesized by Iida-
Klein, this difference might be due to a difference in posture,(40) and sheep have a 
posture closer to mice than to human. 
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ITS also showed site-dependent results. In femur, rN and rBV/TV increased 
whereas pBV/TV decreased. In vertebra, rTb.Th decreased whereas pTb.Th and 
pBV/TV in the oblique direction had a trend towards an increase. Injecting sclerostin 
antibody treatment in monkey model, which has shown to increase bone mineral density 
in vertebra and hip,(41,42) cancellous bone samples from vertebra had increased pTb.Th 
and converted rod- to plate-like trabeculae.(43) Those site-dependent results are likely to 
be associated with different loading conditions and mechanical purpose of the bone. 
 Absence of a greater difference between PTH and Vehicle groups may suggest 
there could be a different optimal duration for PTH treatment in sheep than in human, 
where 24 months of treatment is recommended.(44) Factors like age, because of the age-
dependent effect of PTH treatment,(45) and turnover rate are also to be considered. Other 
studies treated elderly intact-ewes with PTH for only 3 months(38,46) and noted an 
increased bone turnover in iliac crest(38) or only at the lumbar spine.(46) The latter study, 
however, did not find any significant difference in microstructural parameters, 
suggesting that the osteoporotic model using old intact ewes was insufficient to see a 
major treatment effect. One can also consider the fact that two years post ovariectomy 
might not be representative of postmenopausal women turnover anymore because 
several studies showed ovariectomy altered turnover and material properties during the 
first year but after that period the effect stabilized or reduced.(47) 
Despite the fact that no treatment-effect on monotonic strength, the resistance to 
fatigue loading was preserved with PTH treatment. Modulus reduction and energy 
dissipation under cyclic fatigue loading were maintained compared to Vehicle group 
(Figure 1). No one has studied the fatigue properties with PTH treatment in cancellous 
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bone with ovariectomized sheep model. In addition, fatigue loading occurs more 
frequently than traumatic single-overload. In cortical bone from these same sheep, we 
have shown increased fatigue life with PTH treatment compared to other anti-resorptive 
agents(48) and no difference in whole bone bending strength (Chen et al cortical paper). 
Therefore, PTH seems to affect fatigue behavior of bone tissue rather than monotonic 
resistance.   
Tissue mineralization has shown to increase as tissue ages.(7,49) Therefore, 
decreased mineralization from Raman spectroscopy with PTH treatment indicated 
younger bone tissue in femur. 77% of the variation in energy dissipation was explained 
by rBV/TV and mineralization (Table 5). This correlation suggested that the 
preservation of mechanical properties before fatigue failure resulted from increased rod-
type trabeculae and mineralization. Moreover, Torres et al. also showed rod-type 
trabeculae were important for initiation of fatigue failure.(50)  
FTIRI did not show any significant difference in mineral-to-matrix ratio in the 
iliac crest and vertebra whereas Raman had decreased mineral-to-matrix ratio in femur. 
Ovariectomized monkeys treated with PTH for 18 months had a decrease in mineral-to-
matrix ratio.(33) Similarly, in iliac crest biopsies from PTH–treated women with fractures 
contrasting to women who received no anabolic agent, had decreased mineral-to-matrix 
levels in cancellous bone.(31,51) Besides, acid phosphate substitution ratio from FTIRI, 
indicating new mineral formation, was not different between groups; perhaps due to the 
slow turnover rate in the sheep.  
Carbonate-to-phosphate ratio was decreased compared to baseline (13 month), 
indicating there was increased remodeling in this model.(52) An increase in turnover with 
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PTH with a decrease in carbonate-to-phosphate ratio was similarly reported in PTH-
treated intact mice.(53) There was no difference in carbonate-to-phosphate ratio in the 
human study of PTH-treated fractured patients, resulting from the small sample size.  
Crystallinity was lower in the PTH-treated ewes at completion of the study, 
suggesting PTH prevented the increase of crystallinity caused by ovariectomy.(31,51) 
Crystallinity was also decreased in PTH-treated ovariectomized monkeys,(33) in PTH-
treated women with fractures,(31) and in PTH-treated women for 19-24 months.(54) 
Similar lack of increase in collagen crosslink ratio had been reported in the PTH-treated 
ovariectomized monkeys(33) and PTH-treated women with fractures.(31) In agreement 
with the trend measured in the vertebra, decreases were reported in mice treated with 
PTH(55) and  PTH-treated women.(54) 
Heterogeneity of the bone matrix is important for preventing proliferation of 
micro-cracks.(10,56) Osteoporosis and bisphosphonate treatment decreased heterogeneity 
in human bone.(35,57) Our hypothesis was that PTH treatment, stimulating bone 
formation, would prevent the loss or increase heterogeneity in bone matrix. At micro-
level, the heterogeneity of mineral-to-matrix ratio was decreased in Vehicle group but 
not in PTH-treated iliac crest. Unlike the increased heterogeneity in iliac crest of 
osteoporotic patients,(58) PTH prevented the loss in mineral-to-matrix heterogeneity in 
current study. Carbonate-to-phosphate ratio heterogeneity increased in the PTH group 
but the increase was less than in the Vehicle group; this unexpected result may be due 
to large standard deviations. The crystallinity heterogeneity was reduced in the PTH 
group but less than in the Vehicle group, which showed that PTH partially prevented 
the loss in crystallinity heterogeneity. Overall the heterogeneities were maintained or 
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increased as a consequence to PTH treatment, validating our hypothesis.  
Focusing on newly formed bone at nano-level to characterize PTH treatment 
effect on the maturation process, AFM-IR measured higher mineral, higher collagen 
content and collagen maturity in PTH group. In more mature bone tissue, mineral-to-
matrix ratio and acid phosphate substitution ratio were lower in the PTH group, 
suggesting new bone tissue was more youthful but with areas of high mineral maturity. 
These findings indicated that PTH treatment accelerated bone formation, but once the 
bone was mature, the mineral-to-matrix ratio tended to decrease as evidenced by 
Paschalis et al..(54)  
More interestingly, AFM-IR was able to observe variations during the 
maturation process of new bone in both PTH- and saline-treated samples. An increase 
in mineral-to-matrix ratio and a decrease in acid phosphate substitution ratio during 
bone maturation were captured. Previous studies found the same variations with bone 
maturity.(59) For instance, Gourion et al. and Paschalis et al. found increased mineral-to-
matrix ratio and crystallinity with distance from osteon center in baboon femur and 
human iliac crest.(49,57) 
This study has several limitations.  The extent of osteoporosis in our saline-
treated sheep was not severe, suggesting additional stresses are needed to mimic human 
condition. Additionally, for economic reasons, we did not have parallel normal controls. 
Moreover, the duration for PTH treatment in sheep is not established, and the anabolic 
window(60) may be different from that in humans. Ovariectomized old sheep in the 
current study might have a low turnover, resulting low possibility to see a major 
treatment effect.  
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In conclusion, utilizing ovariectomized-mature ewes placed on a metabolic 
acidosis diet for one year prior to PTH treatment, we were able to verify our hypothesis 
that PTH treatment preserved mechanical properties during fatigue loading by 
maintaining/improving tissue heterogeneity. Monotonic behavior was not different with 
PTH treatment compared to Vehicle group, which might indicate that PTH treatment 
altered fatigue behavior rather than monotonic behavior. PTH treatment partially 
prevented the loss of bone quality parameters (microarchitecture and composition) in 
femur and iliac crests but did not seem to be as effective in the vertebra, confirming a 
site-dependent effect of PTH treatment. We also correlated increased rod-type 
trabeculae and decreased mineralization with maintained energy dissipation, 
corresponding the alterations in tissue properties and microstructures contributed to 
resistance to fatigue loading. Moreover, an accelerated bone formation process as a 
consequence of PTH treatment was captured in a novel nanoscale spectroscopic method. 
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CHAPTER 4 
ROLE OF CORTICAL BONE MICROSTRUCTURE AND ANISOTROPY OF 
FRACTURE TOUGHNESS IN TISSUE FAILURE* 
 
 
4.1   Introduction 
 
Cortical bone is a relatively complex hierarchical material composed of fibers 
(osteons) within an interstitial matrix, similar to fiber-reinforced composites. 
Haversian canals with blood vessels are located in the middle of osteons. The interface 
between osteons and surrounding interstitial matrix is demonstrated by a cement line 
that behaves as a weak interface. This microstructural morphology is a critical to the 
mechanical properties of the tissue and determines the crack growth trajectory in 
cortical bone during failure. The presence of osteons reduced the strength and modulus 
of cortical bone but increased toughness by deviating or stopping crack propagation (1-
3).  
Fracture toughness, correlated with bone fragility, is a material property that 
determines the resistance to crack propagation when an initial crack is present. The 
relative toughness between two materials, toughness ratio, determines crack behavior 
at interfaces. For example, the cement line to osteon toughness ratio determined 
whether a crack deflected, when the cement line was tougher, or penetrated along the 
cement line, when the osteon was tougher (4,5). However, these simulations assumed 
isotropic fracture toughness, based on available data and simulation methods.  
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Experimentally, fracture toughness of cortical bone can be determined at the 
microscale. Fracture toughness in cortical bone increases as a crack propagates (6,7). In 
addition, fracture toughness is higher in the transverse than in the longitudinal 
direction (8,9). To date measurements have focused mainly on longitudinal fracture in 
which a crack propagates parallel to the axis of the osteons. However, clinically the 
relevant crack orientation is transverse for propagation perpendicular to the axis of the 
osteons (6,7,10,11). Bone fracture toughness at the nanoscale is anisotropic and difficult 
to measure. Therefore, anisotropic effects at the nanoscale have been examined using 
simulations (12).  
Linear elastic fracture mechanics (LEFM) has been widely applied to 
characterize mechanical behavior in fiber-reinforced composite models (13,14). Bone 
resistance to fracture has been characterized by LEFM (12,15-18), by measuring fracture 
toughness of cortical bone under tension/compression. However, bending is another 
common loading condition and may be more relevant to clinical events. In a beam 
under bending, the stress state varies with location and will be influenced by the 
microstructure. The effect of the location of osteons on crack propagation and 
effective toughness in the beam is still unknown.  
In the current study, our objective was to use a computational mechanics 
approach to investigate the role of anisotropy of fracture toughness and of altered 
microstructure in crack growth trajectory and force needed to propagate a crack in 
cortical bone under bending, assuming LEFM theory. We altered anisotropy of 
fracture toughness in a beam loaded in three-point bending by including an osteon and 
varying its fracture toughness, location and diameter, and by varying the number of 
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osteons. Our hypothesis was that the force needed to propagate a crack would increase 
with the degree of anisotropy, with more material remaining to resist bending, with 
increasing osteon diameter, and with increasing numbers of osteons.  
 
4.2   Methods 
 
The computational models were analyzed with FRANC2D (Fracture Analysis 
Code, 2 Dimensions), a finite element code for performing fracture mechanics analysis 
of 2D structures under LEFM assumptions. This semi-automated code has been used 
in the engineering literature (19) as a more interactive approach and includes the 
traditional tasks of pre-processing, processing, and post-processing. The main features 
of the code are to automatically refine the mesh around the crack tip (Figure 4.1E) 
without losing unaffected structural information, to predict the crack trajectory in 
mixed-mode fracture, and to calculate the stress intensity factors (20-22). A triangulation 
algorithm generates transition meshes between the extended crack path and the 
unaffected portion of the mesh (20). Quarter-point elements are meshed around the 
crack tip to model the LEFM singularity. Additional refinement of the mesh around 
the crack tip can be specified by the user. Direction of propagation (kink angle) at 
each step is determined by maximum tensile stress theory. Calculations were virtually 
instantaneous and required no user interaction except specifying a crack increment at 
the beginning of each simulation. 
A 2x20 mm, pre-notched (0.05 mm initial crack on tensile side) beam was 
created in FRANC2D and loaded in three-point bending. A plane strain assumption 
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was carried out in the simulations. Initial element side-length was 0.2 mm based on a 
mesh convergence for correct beam bending stresses. As the crack propagated, the 
mesh around the crack tip was refined, and quarter-point elements inserted. The 
interstitial matrix was defined as an isotropic material whereas osteons were modeled 
as a linear elastic, orthotropic material (Table 4.1), assuming osteons and interstitial 
matrix were perfectly bonded. Osteons were perfectly parallel to each other. The 
material properties were based on nanoindentation measurements for elastic moduli 
(23,24) and theoretical calculations for shear moduli and Poisson’s ration (25). 
Anisotropic fracture toughness was based on experimental measurements (9,15).  
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Figure 4.1 A 2x20 mm beam loaded in 3-point bending with pre-notched central crack  
                  of 0.05 mm length. Model geometry for varying cases of (A) anisotropic  
                   fracture toughness of osteon (n = 1 osteon, d = 0.2 mm, KIx = 2 MPa√m,  
                  KIy = 2,4,6,8 MPa√m), (B) osteon location (n = 1 osteon, d = 0.2 mm), (C)  
                  osteon diameter (n = 1 osteon, d = 0.2, 0.4, 0.6, 0.8, 1 mm), (D) osteon  
                  number (n = 1-5 osteon(s), d = 0.2 mm). (E) Meshes were automatically  
                  refined along the crack trajectory. 
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Table 4.1 Material properties of interstitial matrix and osteons for all simulations  
                except when KIy of the single osteon was varied from 2-8 MPa√m (9,23-25).  
 
Interstitial matrix: Isotropic 
 E = 27 GPa G = 7 GPa v = 0.2 KI = 3 MPa√m 
 
Osteon: Orthotropic 
 Ex = 25 GPa Gxy = 7 GPa vxy = 0.2 KIx = 2 MPa√m  
Ey = 17 GPa  vyz = 0.3 KIy = 6 MPa√m 
Ez = 17 GPa  vxz = 0.2 
 
We initially included a single osteon within the beam and altered fracture 
toughness of the osteon (n = 1 osteon, diameter d = 0.2 mm, KIx = 2 MPa√m, KIy = 2, 
4, 6, 8 MPa√m, Figure 4.1A), and its location (n = 1 osteon, diameter d = 0.2 mm in 5 
locations, Figure 4.1B) and diameter (n = 1 osteon, d = 0.2, 0.4, 0.6, 0.8, 1 mm, Figure 
4.1C) for different simulation cases.  Then we increased the number of osteons (n = 1-
5, d = 0.2 mm, Figure 4.1D). In our models, we neglected the contribution from the 
cement line (thickness 1 – 2 µm), which is much smaller than the diameter of the 
osteons (100 – 300 µm). Crack trajectory was examined.  Stress intensity factors were 
calculated by the displacement correlation technique. The effective driving force (Keff) 
at the crack tip was calculated from √(KI2+KII2). To calculate the force needed to 
propagate a crack, we defined the effective fracture toughness (Kceff) for the local 
system as a resisting force. No data on the effective mixed-mode fracture toughness of 
cortical bone were available in the literature. Therefore, the effective mixed-mode 
fracture toughness (Kceff) was defined as a linear function (Figure 4.2), representing 
the local resisting force in the system. With Keff = Kceff, normalized critical load was 
calculated using the ratio, Kceff/Keff, indicating the load needed to propagate a unit 
length of a crack.  
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Figure 4.2 To calculate force needed to propagate a crack requires defining  
                  the effective fracture toughness (Kceff) for the local system as a resisting  
                  force. No available data on the effective mixed-mode fracture toughness of  
                  cortical bone in the literature. The effective mixed-mode fracture  
                  toughness (Kceff) was defined as a linear function, representing the local  
                  resisting force in the system. 
 
 
4.3   Results 
 
We first examined the effect of anisotropy of fracture toughness (Figure 4.3). 
As KIy increased (anisotropy of osteon increased), the crack trajectory moved into the 
longitudinal direction (parallel to the axis of osteon) and the normalized critical load, 
calculated as the ratio of Kceff/Keff, increased (r2 = 0.89, p = 0.06). When we varied the 
location, the normalized critical load of a single osteon was negatively correlated with 
osteon location (r2 = 0.99, p < 0.05, Figure 4.4A).  The adjacent location (blue point in 
Figure 4.4A) was omitted from the regression due to proximity to the initial crack.  
When osteon diameter was increased, normalized critical load increased (r2 = 0.82, p < 
0.05, Figure 4.4B). When multiple osteons were included, normalized critical load was 
positively correlated with the number of osteons. As expected, a beam with 5 osteons 
presented the most resistance to crack propagation (r2 = 0.70, p = 0.08, Figure 4.4C). 
However, the effect of increased numbers of osteons was less than the other 
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parameters examined.  
 
 
Figure 4.3 Crack trajectories for varying fracture toughness KIy of a single osteon. As  
                  KIy increased (KIx = 2 MPa√m), the crack propagated more longitudinally  
                 (parallel to the axis of osteon) and normalized critical load increased (r2 =  
                 0.89, p = 0.06).  
 
 
 
Figure 4.4 Osteon location, diameter and number had differing influences on the  
                  force to propagate the initial crack when loaded in bending. Normalized  
                  critical load (A) decreased with osteon location moving towards the point  
                  of load application (r2 = 0.99, p < 0.05); (B) increased as osteons became  
                  larger (r2 = 0.93, p < 0.05); and, (C) gradually increased with increasing  
                  numbers of osteons (r2 = 0.69, p = 0.08). For the relationship with osteon  
                  location relative to the initial crack, the adjacent location (blue point) was  
  107 
                  omitted from the regression due to proximity to the osteon, as discussed in   
                  the Results.   
 
 
4.4   Discussion 
 
This study used a computational mechanics approach to evaluate the role of 
anisotropy of fracture toughness and of altered microstructure in crack growth 
trajectory and force to propagate a crack in cortical bone. The force needed to 
propagate a crack was higher as the degree of anisotropy increased. In addition, the 
crack propagated more transversely as the ratio of transverse to longitudinal fracture 
toughness increased. Normalized critical load (Kceff/Keff) increased as the number of 
osteons increased, as more material remained to resist bending, and with a thicker 
single osteon.  
With an increasing degree of anisotropy, indicating increased transverse 
fracture toughness, the crack trajectory moved more longitudinally and became more 
parallel to the axis of the osteon (Figure 4.3). Previous experimental studies reported 
lower measured longitudinal fracture toughness (8,9), indicating lower energy was 
needed to propagate in the longitudinal direction (parallel to the axis of osteon). In 
prior simulations, the main determinant for deflecting at or penetrating into an osteon 
was the ratio of strength between the osteon and cement line (26). However, fracture 
toughness in this previous study was modeled as isotropic. In the current study, we 
implemented varying anisotropic fracture toughness values and showed that the crack 
propagation trajectory depended on the ratio of fracture toughness in the transverse 
and longitudinal directions. When the transverse fracture toughness was larger than 
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that in longitudinal direction (anisotropic fracture toughness), the crack propagated 
longitudinally. When applied to the crack morphology observed clinically, this finding 
suggests that the straight crack trajectory present in individuals with AFF could result 
from increased isotropic material properties due to reduced tissue heterogeneity (27). 
Varying osteon location demonstrated the role of the bending stress state and 
the contribution of material resistance to bending. Longitudinal bending stress is 
proportional to 1/h2 according to beam theory (28), in which h is the depth of the 
uncracked (intact) section of the beam. The maximum critical load was for h = 1.3 mm 
when the crack tip exited the single osteon in the first location (-0.7 mm). As the crack 
tip exited from osteons located deeper in the material, less material remained to resist 
bending; therefore, the crack propagated more easily, as indicated by lower critical 
loads (Figure 4.4A).  
The effects of osteon diameter were more complex, reflecting the combined 
effects of bending stress state and material distribution relative to the neutral axis. The 
absence of a Haversian canal in the model osteons was a limitation in this study, 
particularly for the osteon diameter simulation. Experimentally, as osteon size 
increases, Haversian canals are also larger, increasing the porosity of the bone tissue 
and reducing the fracture toughness (11,29). This behavior was not captured by our 
simple osteon model when we altered the diameter. Therefore, to investigate the 
overall fracture toughness of bone, we suggest incorporating porosity in the bone 
tissue in future computational models.  
When additional osteons were modeled, the heterogeneity of the material 
increased, and the load required to propagate cracks increased (Figure 4.4C). This 
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increase was also consistent with experimental measurements in bone of elevated 
fracture toughness with increased density of small osteons (11,29).  
The current study utilized a 2D model to evaluate the contribution of 
microstructural features and fracture toughness to crack trajectory and force needed 
for crack propagation. This model could not capture the crack growth behavior in the 
radial/circumferential plane. Nevertheless, our simulations provide insight into crack 
growth when comparing isotropic and anisotropic material behavior. Another 
limitation of this study was the assumption of a linear relationship for effective 
fracture toughness as a function of mode mixity (Figure 4.2). To calculate normalized 
critical load, representing the required load to propagate a unit of crack, required 
defining the effective fracture toughness for the local system as a resisting force. No 
data on the effective mixed-mode fracture toughness of cortical bone are available in 
the literature. Therefore, the effective fracture toughness values used herein were 
based on experimental data from fracture toughness of cortical bone measured 
individually in both transverse and longitudinal directions (9).  
In summary, the current study provided additional insights into tissue failure at 
the microscale. The anisotropy of cortical bone, osteon location, and osteon numbers 
were critical to increasing the fracture toughness of cortical tissue loaded in bending. 
Cortical bone with more osteons located further away from the applied loads to 
maximize intact material would withstand more load before propagating cracks and 
fracturing.  
 
  
  110 
References 
 
1. O'Brien FJ, Taylor D, Lee TC. The effect of bone microstructure on the 
initiation and growth of microcracks. Journal of Orthopaedic Research. 
2005;23(2):475-80. 
2. Taylor D, Hazenberg JG, Lee TC. Living with cracks: damage and repair in 
human bone. Nature Materials. 2007;6(4):263-8. 
3. Nyman JS, Reyes M, Wang X. Effect of ultrastructural changes on the 
toughness of bone. Micron. 2005;36(7):566-82. 
4. Guo XE, He M, Goldstein SA. Understanding cement line interface in bone 
tissue: a linear fracture mechanics approach. American Society of Mechanical 
Engineering. 1995;29:303-. 
5. Evans AG, He MY, Hutchinson JW. Interface debonding and fiber cracking in 
brittle matrix composites. Journal of the American Ceramic Society. 
1989;72(12):2300-3. 
6. Nalla RK, Kruzic JJ, Kinney JH, Ritchie RO. Effect of aging on the toughness 
of human cortical bone: evaluation by R-curves. Bone. 2004;35(6):1240-6. 
7. Vashishth D. Rising crack-growth-resistance behavior in cortical bone:: 
implications for toughness measurements. Journal of Biomechanics. 
2004;37(6):943-6. 
8. Phelps J, Hubbard G, Wang X, Agrawal C. Microstructural heterogeneity and 
the fracture toughness of bone. Journal of Biomedical Materials Research. 
2000;51(4):735-41. 
9. Koester KJ, Iii JA, Ritchie R. The true toughness of human cortical bone 
measured with realistically short cracks. Nature Materials. 2008;7(8):672. 
10. Wright T, Hayes W. Fracture mechanics parameters for compact bone—effects 
of density and specimen thickness. Journal of Biomechanics. 
1977;10(7):419427-25430. 
  111 
11. Yeni Y, Brown C, Wang Z, Norman T. The influence of bone morphology on 
fracture toughness of the human femur and tibia. Bone. 1997;21(5):453-9. 
12. Ural A, Vashishth D. Anisotropy of age-related toughness loss in human 
cortical bone: a finite element study. Journal of Biomechanics. 
2007;40(7):1606-14. 
13. Müller W, Schmauder S. Stress-intensity factors of r-cracks in fiber-reinforced 
composites under thermal and mechanical loading. International Journal of 
Fracture. 1993;59(4):307-43. 
14. Erdogan F, Gupta G. The inclusion problem with a crack crossing the 
boundary. International Journal of Fracture. 1975;11(1):13-27. 
15. Norman TL, Vashishth D, Burr D. Fracture toughness of human bone under 
tension. Journal of Biomechanics. 1995;28(3):309313-11320. 
16. Bonfield W. Advances in the fracture mechanics of cortical bone. Journal of 
Biomechanics. 1987;20(11-12):1071-81. 
17. Guo X, Liang L, Goldstein S. Micromechanics of osteonal cortical bone 
fracture. Journal of Biomechanical Engineering. 1998;120(1):112-7. 
18. Ural A, Vashishth D. Cohesive finite element modeling of age-related 
toughness loss in human cortical bone. Journal of Biomechanics. 
2006;39(16):2974-82. 
19. Yan X. Automated simulation of fatigue crack propagation for two-
dimensional linear elastic fracture mechanics problems by boundary element 
method. Engineering Fracture Mechanics. 2007;74(14):2225-46. 
20. Bittencourt T, Wawrzynek P, Ingraffea A, Sousa J. Quasi-automatic simulation 
of crack propagation for 2D LEFM problems. Engineering Fracture 
Mechanics. 1996;55(2):321-34. 
21. Wawrzynek PA, Ingraffea A. Interactive finite element analysis of fracture 
processes: an integrated approach. Theoretical and Applied Fracture 
Mechanics. 1987;8(2):137-50. 
  112 
22. Wawrzynek PA, Ingraffea AR. An interactive approach to local remeshing 
around a propagating crack. Finite Elements in Analysis and Design. 
1989;5(1):87-96. 
23. Fan Z, Swadener J, Rho J, Roy M, Pharr G. Anisotropic properties of human 
tibial cortical bone as measured by nanoindentation. Journal of Orthopaedic 
Research. 2002;20(4):806-10. 
24. Donnelly E, Boskey AL, Baker SP, Van der Meulen MC. Effects of tissue age 
on bone tissue material composition and nanomechanical properties in the rat 
cortex. Journal of Biomedical Materials Research. 2010;92(3):1048-56. 
25. Yoon YJ, Cowin SC. An estimate of anisotropic poroelastic constants of an 
osteon. Biomechanics and Modeling in Mechanobiology. 2008;7(1):13-26. 
26. Mischinski S, Ural A. Finite element modeling of microcrack growth in 
cortical bone. Journal of Applied Mechanics. 2011;78(4):041016. 
27. Lloyd AA, Gludovatz B, Riedel C, et al. Atypical fracture with long-term 
bisphosphonate therapy is associated with altered cortical composition and 
reduced fracture resistance. Proceedings of the National Academy of Sciences. 
2017:201704460. 
28. Davies J, Leach P. First-order generalised beam theory. Journal of 
Constructional Steel Research. 1994;31(2-3):187-220. 
29. McCalden RW, McGeough JA, Barker MB. Age-related changes in the tensile 
properties of cortical bone. The relative importance of changes in porosity, 
mineralization, and microstructure. The Journal of Bone and Joint Surgery. 
1993;75(8):1193-205. 
 
 
 
 
 
 
  
  113 
CHAPTER 5 
SUMMARY AND FUTURE DIRECTIONS 
 
5.1   Summary 
 
Osteoporosis decreases bone quantity and quality(1-4). In addition to adverse changes in 
bone geometry and density, osteoporosis decreases apparent level strength and 
stiffness(5,6). Furthermore, bone tissue mineralization is reduced, and carbonate 
substitution and crystallinity are increased in animal models and patients(1,7). 
Parathyroid hormone (PTH) is an FDA-approved anabolic osteoporosis treatment that 
increases bone mass and density in animal studies(8-10); however, little is known about 
its effect on bone tissue composition and mechanics. Moreover, few studies have 
utilized a larger animal model, such as the sheep, with Haversian remodeling. Thus, 
the objectives of this work were first to examine the alterations of mechanical and 
material properties of cortical bone, and secondly of cancellous bone, with PTH 
treatment utilizing osteopenia sheep model. Tissue failure at the microscale is 
primarily affected by heterogeneity of material properties such as fracture toughness 
and microstructure(11,12). To understand bone fragility, fracture behavior of bone at the 
tissue level should be examined. Fracture toughness of bone is anisotropic, but 
difficult to measure; anisotropic effects can be examined using simulations. Therefore, 
to gain additional insights into fracture behavior, we investigated the contributions of 
microstructure and fracture toughness to crack propagation using computational 
simulations as the third portion of this research.  
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We used an osteopenic sheep model to investigate the effects of PTH on mechanical 
performance and tissue properties of cortical bone. The effect of PTH treatment on the 
femur in the sheep model was greater at the micro- and nanoscale than at the whole 
bone level. The whole bone properties of the PTH-treated and vehicle groups were not 
different. PTH-treated bone tissue had lower fracture toughness and higher osteon 
density. At the tissue-level, PTH treatment also increased mineralization, decreased 
indentation modulus, and decreased hardness. Millimeter and nano-scale material 
properties were correlated with whole bone bending strength: fracture toughness and 
crystallinity explained 63% of the variation in whole-bone bending strength, but 
fatigue properties correlated little with whole bone bending strength or fracture 
toughness.  
 
Although fracture toughness correlated with whole bone bending strength, the changes 
in fracture toughness were not evident at the whole bone level through differences in 
bending strength. Mechanical failure of a whole bone may occur from a single load, 
which is sensitive to whole bone strength, from cyclic loading that is sensitive to 
fatigue life, or from sensitivity to crack growth, reflected by fracture toughness. The 
altered tissue properties measured here reflected alterations in fatigue life and fracture 
toughness, which would cause mechanical failure independent of whole bone strength 
changes. In a short summary, the alterations at nano- and micro-scale contributed to 
tissue properties that describe bone failure; moreover, this study is the first to compare 
three mechanical failure properties: whole bone strength, fracture toughness, fatigue 
behavior.  
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Secondly, the effects of PTH treatment on bone tissue composition and mechanics of 
cancellous bone in an osteopenia sheep model were examined. Sheep treated with 
PTH gained less weight, analogous to PTH-treated humans who also lost weight, 
attributed to mild hypercalcemia reducing apatite(13). PTH-treated samples experienced 
less energy dissipation before fatigue failure than those in the vehicle group. For 
microstructural measures, PTH increased the volume fraction of rod-type trabeculae 
and decreased mineralization. Correlating tissue composition, microstructure, and 
mechanical performance, 77% of the variation in energy dissipation was explained by 
volume fraction of rods and mineralization. When we examined tissue heterogeneity, 
carbonate-to-phosphate heterogeneity was increased and mineral-to-matrix 
heterogeneity was maintained with PTH treatment. Moreover, the results from AFM-
IR showed the PTH-treated group had higher mineral-to-matrix ratio, crystallinity and 
collagen crosslink ratio and lower acid phosphate substitution ratio, in agreement with 
a faster tissue maturation process. In summary, our findings showed that PTH altered 
microarchitecture, material properties, and tissue heterogeneity to improve 
maintenance of mechanical properties following cyclic loading.  
 
The third portion of this research modeled the fracture behavior of cortical bone at the 
tissue level. The role of anisotropy of fracture toughness and of altered microstructure 
in crack trajectory and the force needed to propagate a crack was investigated. When 
we examined the effect of anisotropy of fracture toughness, as the anisotropy of 
osteons increased (KIy) the crack trajectory propagated more longitudinally and the 
normalized critical load, calculated as the ratio of Kceff/Keff, increased. Considering the 
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effect of osteon location, the normalized critical load of a single osteon was negatively 
correlated with osteon location. When osteon diameter was increased, the normalized 
critical load increased. When multiple osteons were included, normalized critical load 
was positively correlated with number of osteons. As expected, a beam with more 
osteons presented the most resistance to crack propagation. In the first study, 
presented in Chapter 2, PTH increased osteon density and decreased fracture 
toughness in cortical bone tissue, which contradicts the simulation results (Chapter 4). 
Although resistance to crack propagation increased with increasing numbers of 
osteons, the central Haversian canal of the osteons was not included in the simulations. 
In addition to the Haversian canal of osteons, higher turnover rate induced by PTH 
treatment might decrease fracture toughness directly, which cannot be simulated in the 
model. In summary, the anisotropy of cortical bone, osteon location, and osteon 
numbers were critical to increasing the fracture toughness of cortical tissue loaded in 
bending. Cortical bone with more osteons located further away from the applied loads 
would withstand more load before propagating cracks and fracturing.  
 
The first two studies presented in this body of work used an osteopenic sheep model to 
examine the effects of PTH treatment on mechanical and material properties in 
cortical and cancellous bone. In both bone types, PTH treatment affected fatigue 
behavior rather than resistance to monotonic loading, which could contributed to the 
53% reduction in osteoporosis fracture risk seen clinically(14). Fatigue life in cortical 
bone tissue was increased compared to bisphosphonate-treated samples whereas 
energy dissipation of cancellous bone under cyclic loading was preserved with PTH 
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treatment before failure. Alterations in tissue composition with PTH treatment were 
more evident at cancellous sites. Tissue heterogeneity was increased and 
mineralization was decreased in cancellous bone with PTH treatment. Correlations 
between microstructural features and mechanical and material properties were present 
in both bone tissue types. To our knowledge we are the first to investigate the 
contribution of anisotropic fracture toughness to crack propagation in bone at the 
tissue level, providing additional insights into tissue failure at the microscale and the 
cortical data presented in Chapter 2. Continued research into the alterations of material 
properties and microstructural features in bone tissue with aging and/or treatments will 
yield important information regarding fracture mechanisms.  
 
5.2   Future Directions 
 
Results of the three studies presented in this thesis have identified several future 
directions that can be divided roughly into two categories: continued and new research 
avenues. Continued research avenues include analysis of other anabolic osteoporosis 
treatments and three-dimensional anisotropic simulations of crack behavior. New 
research avenues include additional characterization techniques, combinations of drug 
holiday and sequential treatments, and bone tissue engineering.  
 
5.2.1   Continued Research Avenues 
 
5.2.1.1 Continued Osteoporosis Treatment Analysis 
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Investigating and comparing new anabolic osteoporosis treatments with PTH and anti-
resorptive agents can help us to obtain a better understanding of treatment 
mechanisms. Abaloparatide (ABL), an anabolic osteoporosis treatment approved by 
the FDA less than a year ago, has been shown to reduce fracture risk by 57%(15). ABL 
increases bone formation but not bone resorption, whereas teriparatide (PTH), 
investigated in this thesis, increases both bone formation and resorption, limiting bone 
mineral density gains(16,17); thus, PTH-treated samples had increased porosity and less 
cortical bone formation(18). ABL reduces the risk of both vertebral and non-vertebral 
fractures whereas PTH decreases the risk of vertebral fractures only(15,19,20). In rat 
models, ABL increases bone mass and density in the femur and vertebrae, and 
monotonic compressive strength on vertebrae(21). In clinical trials, bone mineral 
density is increased with ABL compared to placebo and PTH groups(22). However, 
biomechanical properties such as fatigue behavior and tissue composition of ABL-
treated bone are still unknown. Similar to the aims in this thesis, a better 
understanding of normal and osteoporotic bone function can be provided by 
determining the correlations between mechanical performance across different length-
scales and tissue material properties. 
 
5.2.1.2 Continued Three-dimensional Anisotropic Simulation 
 
Our simulations are the first to examine anisotropic fracture properties. However, one 
of the limitations of our approach in Chapter 4 is the assumption that osteons are 
perfectly parallel to each other. By altering the orientations of osteons, cracks could 
propagate into the radial/circumferential plane, which would require a three-
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dimensional simulation. FRANC3D can be utilized and taken the advantages of 
refining mesh along the crack tip. Models with osteons oriented 0, 30, 45, 60 degrees 
relative to the longitudinal direction can be examined. The results from the models 
will help us understand crack behavior in three dimensions with anisotropic fracture 
toughness and varying microstructures.   
 
5.2.2   New Research Avenues 
 
5.2.2.1 New Synchrotron Imaging Methods 
 
Additional characterization techniques, such as transmission x-ray microscopy (TXM) 
with synchrotron radiation, can be applied to examine microstructures and tissue 
mineralization at nanoscale. TXM with synchrotron radiation is a novel imaging 
technique(23). A monochromatic x-ray source is used to image samples through x-ray 
transmission, absorption and scattering. This method has been used for nondestructive 
high-resolution (approximately 30 nm) imaging and quantification of tissue 
mineralization(24). Two dimensional images can be collected from TXM, and after 
imaging processing of tiling individual images, a 3D tomography of a structure is 
created(25). Applying this technique to bone samples, the lacunar-canalicular network 
can be visualized, exploring the complex interconnected bone cell network(26). 
Changes in lacunar-canalicular properties can affect the tissue permeability, which is 
important to bone nutrition and mechanotransduction(27,28). In addition to  
mechanotransduction, critical contributors to fracture, such as microdamage and 
mineralization, can be investigated in three dimensions using synchrotron 
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imaging(29,30). Applying this new technique to characterize tissue microstructural 
features and tissue mineralization will allow us to better understand the role of 
osteoporosis treatment at the nanoscale, and the effects on mechanotransduction, 
microdamage and mineralization that might ultimately affect the fracture risk.  
 
5.2.2.2 New Combinations of Drug Holiday and Sequential Treatments 
 
The effects of PTH treatment have been investigated and presented in Chapters 2 and 
3. PTH treatment alone increased fatigue strength but did not have positive effects on 
whole bone strength; thus, a drug holiday and/or sequential treatments should be 
considered. Moreover, the combination of treatments (drug holiday, anabolic/anti-
resorptive agents) that would best serve osteoporotic patients is still unclear. For 
sequential treatments, patients with treated with PTH during the first year and a 
bisphosphonate for the second year had increased BMD at the hip and spine after the 
first year and maintained BMD in the spine after the second year. On the other hand, 
patients with 2-years of PTH treatment had progressively increasing BMD in both hip 
and spine(31-33). BMD decreased with PTH treatment for one year followed by one-
year of placebo(32). Long-term use of bisphosphonates in patients has shown 
unexpected adverse events such as osteonecrosis of jaw(34), atypical femoral 
fractures(35), and atrial fibrillation(36); thus, a drug holiday after 5 years of treatment is 
considered for patients who are not at high risk for fracture(37). Fracture risk was 
increased in patients who received 2-years of bisphosphonate treatment and up to 1-
year drug holiday,(38) whereas women who received approximately 5 years of 
bisphosphonate treatment did not have increased fracture risk(39,40). Continued 
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bisphosphonate treatment beyond 5 years had little benefit for BMD(41,42). Even with 
all the clinical data, the optimal duration of therapy and the length of the holiday are 
still unknown. At present patients must assess the benefits and risk individually. Thus, 
for future studies, we can use the same sheep model as presented in this thesis, with 
several modifications including a Sham-operated group, treatment with PTH for 1 year 
followed by one year of alendronate treatment; or, 5 years of alendronate treatment 
followed by one year of drug holiday or one year of PTH treatment. 
 
5.2.2.3 New Tissue Engineering 
 
Beyond additional experimental techniques and comparison of other osteoporosis 
treatments, the knowledge of bone fracture behavior can be applied to tissue 
engineering and 3D tissue printing. Three dimensional printing (3DP) is a powder-
based freeform fabrication method developed in the early 1990s(43). The important 
parameters that control the quality of 3DP scaffolds are powder-packing density, 
powder flowability, layer thickness, binder drop volume and powder wettability(44); 
thus, extensive optimization is needed to generate high-quality 3DP scaffolds. Several 
combinations of the material-binder system currently are used in 3DP bone 
scaffolds(44). For example, starch-based scaffolds are biocompatible and can have the 
similar mechanical strength as trabecular bone(45). The effective pore size on human 
fetal osteoblasts (hFOB) was studied in TCP scaffolds(46); new bone formation was 
observed at the interconnected micro-pores in TCP scaffolds in the rat distal femur(47). 
CaP ceramics scaffolds are widely used because of good osteoconductivity, bioactivity 
such as capillaries and vessel formation, and similarities to bone composition(48). 
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Osteoclast-like cells were confirmed with TRAP stained in CaP ceramics scaffolds(49). 
However, 3DP has limitations. Two major limitations include poor mechanical 
performance and required minimum struts distance. Scaffolds made from TCP had a 
maximum compressive strength of 10.95 MPa(46) but compressive stiffness and yield 
strength have not been reported. Because of the low mechanical strength, most 
scaffolds are used in non-load bearing applications. On the other hand, a minimum 
struts distance is required so that the pore size of scaffolds has to be larger than 300 
µm(50); therefore, highly porous scaffolds are difficult to print.  
 
3DP technology has great advantages for producing defined shapes with controlled 
porosity bone scaffolds, allowing medical device to be customized for patients. 
Applying the knowledge obtained in this thesis can help design optimized bone 
scaffold structures. For example, the volume fraction of rod-type trabeculae and 
mineralization were correlated with fatigue behavior compared to osteoporotic 
cancellous bone in sheep (Chapter 3). Therefore, if we can design the bone scaffolds 
with a great proportion of rod-like microstructure and lower mineralization, the 
scaffolds should preserve mechanical performance during cyclic loading. Specifically, 
finding the appropriate microstructural features for bone scaffolds to resist fatigue 
loading is possible and can be tested.  
 
In summary, several future directions can be investigated based on the findings in this 
thesis. Analyzing another anabolic osteoporosis treatment, Abaloparatide, can provide 
more understanding of normal and osteoporotic bone function. Altering orientations of 
osteons in simulation models will help us understand crack behavior in three 
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dimensions with anisotropic fracture toughness and varying microstructures. Applying 
TXM imaging techniques can characterize tissue microstructural features and tissue 
mineralization, providing better understanding to the role of osteoporosis treatment at 
nanoscale, such as mechanotransduction, microdamage and mineralization, which 
might ultimately affect the fracture risk. For sequential and drug holiday study 
designs, we can use the same sheep model as presented here and include additional 
treatment groups to compare the outcomes of combining PTH and alendronate or 
including drug holidays. Last but not least, by taking the advantage of three 
dimensional printing, finding the appropriate microstructural features for bone 
scaffolds to resist fatigue loading would be possible.    
  
  124 
References 
 
1. McCreadie BR, Morris MD, Chen TC, et al. Bone tissue compositional 
differences in women with and without osteoporotic fracture. Bone. 
2006;39(6):1190-5. 
2. Burket JC, Brooks DJ, MacLeay JM, Baker SP, Boskey AL, van der Meulen MC. 
Variations in nanomechanical properties and tissue composition within trabeculae 
from an ovine model of osteoporosis and treatment. Bone. 2013;52(1):326-36. 
3. Seeman E, Martin TJ. Co-administration of Antiresorptive and Anabolic Agents: 
A Missed Opportunity. Journal of Bone and Mineral Research. 2015;30(5):753-
64. 
4. Boskey A, Mendelsohn R. Infrared analysis of bone in health and disease. Journal 
of biomedical optics. 2005;10(3):031102-0311029. 
5. Zioupos P, Currey J. Changes in the stiffness, strength, and toughness of human 
cortical bone with age. Bone. 1998;22(1):57-66. 
6. McCalden RW, McGeough JA. Age-related changes in the compressive strength 
of cancellous bone. The relative importance of changes in density and trabecular 
architecture. JBJS. 1997;79(3):421-7. 
7. Gadeleta S, Boskey A, Paschalis E, et al. A physical, chemical, and mechanical 
study of lumbar vertebrae from normal, ovariectomized, and nandrolone 
decanoate-treated cynomolgus monkeys (Macaca fascicularis). Bone. 
2000;27(4):541-50. 
8. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. 
Increased bone formation by prevention of osteoblast apoptosis with parathyroid 
hormone. The Journal of clinical investigation. 1999;104(4):439-46. 
9. Oxlund H, Ejersted C, Andreassen T, Tørring O, Nilsson M. Parathyroid hormone 
(1-34) and (1-84) stimulate cortical bone formation both from periosteum and 
endosteum. Calcified tissue international. 1993;53(6):394-9. 
10. Fox J, Miller M, Newman M, Recker R, Turner C, Smith S. Effects of daily 
treatment with parathyroid hormone 1–84 for 16 months on density, architecture 
  125 
and biomechanical properties of cortical bone in adult ovariectomized rhesus 
monkeys. Bone. 2007;41(3):321-30. 
11. Akkus O, Yeni YN, Wasserman N. Fracture mechanics of cortical bone tissue: a 
hierarchical perspective. Critical Reviews™ in Biomedical Engineering. 
2004;32(5&6). 
12. Wang X, Puram S. The toughness of cortical bone and its relationship with age. 
Annals of biomedical engineering. 2004;32(1):123-35. 
13. Schafer AL, Sellmeyer DE, Schwartz AV, et al. Change in undercarboxylated 
osteocalcin is associated with changes in body weight, fat mass, and adiponectin: 
parathyroid hormone (1-84) or alendronate therapy in postmenopausal women 
with osteoporosis (the PaTH study). The Journal of Clinical Endocrinology & 
Metabolism. 2011;96(12):E1982-E9. 
14. Greenblatt D. Treatment of postmenopausal osteoporosis. Pharmacotherapy: The 
Journal of Human Pharmacology and Drug Therapy. 2005;25(4):574-84. 
15. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new 
vertebral fractures in postmenopausal women with osteoporosis: a randomized 
clinical trial. Jama. 2016;316(7):722-33. 
16. Potts JT, Gardella TJ. Progress, paradox, and potential. Annals of the New York 
Academy of Sciences. 2007;1117(1):196-208. 
17. Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of teriparatide and 
strontium ranelate on bone biopsies and biochemical markers of bone turnover in 
postmenopausal women with osteoporosis. Journal of Bone and Mineral 
Research. 2009;24(8):1358-68. 
18. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or 
combined, in women with postmenopausal osteoporosis: the DATA study 
randomised trial. The Lancet. 2013;382(9886):50-6. 
19. Hadji P, Zanchetta J, Russo L, et al. The effect of teriparatide compared with 
risedronate on reduction of back pain in postmenopausal women with osteoporotic 
vertebral fractures. Osteoporosis International. 2012;23(8):2141-50. 
  126 
20. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-
induced osteoporosis. New England Journal of Medicine. 2007;357(20):2028-39. 
21. Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G. Six 
weeks of daily abaloparatide treatment increased vertebral and femoral bone 
mineral density, microarchitecture and strength in ovariectomized osteopenic rats. 
Calcified tissue international. 2016;99(5):489-99. 
22. Leder BZ, O'dea LSL, Zanchetta JR, et al. Effects of abaloparatide, a human 
parathyroid hormone-related peptide analog, on bone mineral density in 
postmenopausal women with osteoporosis. The Journal of Clinical Endocrinology 
& Metabolism. 2015;100(2):697-706. 
23. Andrews J, Brennan S, Pianetta P, et al. Full-field transmission x-ray microscopy 
at SSRL.  Journal of Physics: Conference Series: IOP Publishing; 2009. p. 
012002. 
24. Andrews JC, Almeida E, van der Meulen MC, et al. Nanoscale X-ray microscopic 
imaging of mammalian mineralized tissue. Microscopy and Microanalysis. 
2010;16(3):327-36. 
25. Liu Y, Meirer F, Williams PA, Wang J, Andrews JC, Pianetta P. TXM-Wizard: a 
program for advanced data collection and evaluation in full-field transmission X-
ray microscopy. Journal of synchrotron radiation. 2012;19(2):281-7. 
26. Pacureanu A, Langer M, Boller E, Tafforeau P, Peyrin F. Nanoscale imaging of 
the bone cell network with synchrotron X-ray tomography: optimization of 
acquisition setup. Medical physics. 2012;39(4):2229-38. 
27. Gailani G, Benalla M, Mahamud R, Cowin SC, Cardoso L. Experimental 
determination of the permeability in the lacunar-canalicular porosity of bone. 
Journal of biomechanical engineering. 2009;131(10):101007. 
28. Burger EH, Klein-Nulend J. Mechanotransduction in bone—role of the lacuno-
canalicular network. The FASEB Journal. 1999;13(9001):S101-S12. 
29. Larrue A, Rattner A, Peter Z-A, et al. Synchrotron radiation micro-CT at the 
micrometer scale for the analysis of the three-dimensional morphology of 
microcracks in human trabecular bone. PLoS one. 2011;6(7):e21297. 
  127 
30. Brock GR, Kim G, Ingraffea AR, Andrews JC, Pianetta P, van der Meulen MC. 
Nanoscale examination of microdamage in sheep cortical bone using synchrotron 
radiation transmission x-ray microscopy. PloS one. 2013;8(3):e57942. 
31. Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe 
postmenopausal osteoporosis after teriparatide: final results of the randomized, 
controlled European Study of Forsteo (EUROFORS). Journal of bone and mineral 
research. 2009;24(4):726-36. 
32. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year 
of parathyroid hormone (1–84) for osteoporosis. New England Journal of 
Medicine. 2005;353(6):555-65. 
33. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in 
osteoporotic women with parathyroid hormone followed by alendronate. The 
Journal of Clinical Endocrinology & Metabolism. 2000;85(6):2129-34. 
34. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the 
jaw: report of a task force of the American Society for Bone and Mineral 
Research. Journal of Bone and Mineral Research. 2007;22(10):1479-91. 
35. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal 
femoral fractures: report of a task force of the American Society for Bone and 
Mineral Research. Journal of Bone and Mineral Research. 2010;25(11):2267-94. 
36. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. New 
England Journal of Medicine. 2007;356(18):1895-6. 
37. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for 
osteoporosis: benefits, risks, and drug holiday. The American journal of medicine. 
2013;126(1):13-20. 
38. Curtis JR, Westfall A, Cheng H, Delzell E, Saag K. Risk of hip fracture after 
bisphosphonate discontinuation: implications for a drug holiday. Osteoporosis 
international. 2008;19(11):1613. 
39. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis—
where do we go from here? New England Journal of Medicine. 
2012;366(22):2048-51. 
  128 
40. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping 
alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term 
Extension (FLEX): a randomized trial. Jama. 2006;296(24):2927-38. 
41. Food, Administration D. Background document for meeting of Advisory 
Committee for reproductive health drugs and drug safety and risk management 
advisory committee. Center for Drug Evaluation and Research. 2011:17-20. 
42. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing 
bisphosphonate treatment for osteoporosis—for whom and for how long? New 
England Journal of Medicine. 2012;366(22):2051-3. 
43. Sachs EM, Haggerty JS, Cima MJ, Williams PA. Three-dimensional printing 
techniques. Google Patents; 1994. 
44. Bose S, Vahabzadeh S, Bandyopadhyay A. Bone tissue engineering using 3D 
printing. Materials Today. 2013;16(12):496-504. 
45. Salgado A, Coutinho O, Reis R. Novel starch-based scaffolds for bone tissue 
engineering: cytotoxicity, cell culture, and protein expression. Tissue engineering. 
2004;10(3-4):465-74. 
46. Tarafder S, Balla VK, Davies NM, Bandyopadhyay A, Bose S. Microwave-
sintered 3D printed tricalcium phosphate scaffolds for bone tissue engineering. 
Journal of tissue engineering and regenerative medicine. 2013;7(8):631-41. 
47. Tarafder S, Davies NM, Bandyopadhyay A, Bose S. 3D printed tricalcium 
phosphate bone tissue engineering scaffolds: effect of SrO and MgO doping on in 
vivo osteogenesis in a rat distal femoral defect model. Biomaterials Science. 
2013;1(12):1250-9. 
48. Becker ST, Bolte H, Schünemann K, et al. Endocultivation: the influence of 
delayed vs. simultaneous application of BMP-2 onto individually formed 
hydroxyapatite matrices for heterotopic bone induction. International journal of 
oral and maxillofacial surgery. 2012;41(9):1153-60. 
49. Detsch R, Schaefer S, Deisinger U, Ziegler G, Seitz H, Leukers B. In vitro-
osteoclastic activity studies on surfaces of 3D printed calcium phosphate 
scaffolds. Journal of biomaterials applications. 2011;26(3):359-80. 
  129 
50. Khalyfa A, Vogt S, Weisser J, et al. Development of a new calcium phosphate 
powder-binder system for the 3D printing of patient specific implants. Journal of 
Materials Science: Materials in Medicine. 2007;18(5):909-16. 
 
 
 
 
  
  130 
APPENDIX A: CHAPTER 2 DATA 
 
Table A.1: Whole bone mechanical testing (4-point bending) for femurs of sheep used 
in the study in Chapter 2 
 
Sample ID Group 
Moment of inertia 
(cm4) 
Bending stiffness 
(N-m2) 
Bending strength 
(N-m) 
e191-1 Vehicle 0.80 70.3 169 
e191-2 Vehicle 2.29 103.8 138 
e191-3 Vehicle 1.27 94.8 148 
e191-4 Vehicle 1.77 107.1 168 
e191-5 Vehicle 1.81 70.5 104 
e191-6 Vehicle 2.27 103.7 141 
e191-7 PTH 4.31 94.7 116 
e191-8 PTH 1.44 135.3 160 
e191-9 PTH 1.93 130.1 192 
e191-10 PTH 1.09 105.0 143 
e191-11 PTH 1.56 79.7 118 
e191-12 PTH 2.01 108.7 188 
e191-13 PTH 2.41 113.3 220 
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Table A.2: Fatigue testing, fracture toughness testing and SEM data for cortical beams 
from mid-diaphyseal femurs of sheep used in the study in Chapter 2 
 
Sample ID Group 
Initial 
modulus 
(GPa) 
Cycles to 
failure 
Modulus 
loss at 
failure (%) 
Fracture 
toughness 
(Mpa√m) 
Osteon 
density 
(#/mm2) 
Crack 
Length 
(Pixel) 
e191-1 Vehicle 21.04 2006 23.49 7.17 20 59.998 
e191-2 Vehicle 29.59 9629 34.27 5.69 15 57.45 
e191-3 Vehicle 25.86 31351 NA 6.17 7 45.43 
e191-4 Vehicle 26.5 4270 14.89 4.97 12 70.642 
e191-5 Vehicle 31.29 1338 18.87 6.77 6 75.04 
e191-6 Vehicle 29.5 2390 17.42 6.69 15 70.37 
e191-7 PTH 28.01 23819 38.45 5.16 19 59.934 
e191-8 PTH 24.44 47314 27.94 3.96 14 48.684 
e191-9 PTH 30.36 11159 20.58 3.20 27 NA 
e191-10 PTH 27.26 45447 37.31 7.15 16 72.094 
e191-11 PTH NA NA NA 5.51 43 NA 
e191-12 PTH 28.26 1908 15.29 4.64 37 58.41 
e191-13 PTH 24.79 31501 26.3 4.13 36 52.32 
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Table A.3: Nanomechanical and tissue composition data for mid-diaphyseal cortical 
bone of sheep used in the study in Chapter 2 
 
Sample ID Group Distance (%) 
Er  
(GPa) 
H  
(MPa) Min : Mat CO : PO Crystallinity 
Peak 
height 
ratio 
e191-1 Vehicle 10.0% 29.28 1127.00 6.39 0.216 0.038 1.52 
e191-1 Vehicle 17.4% 30.55 1101.58 6.62 0.223 0.038 1.44 
e191-1 Vehicle 24.7% 31.72 1150.43 7.01 0.218 0.037 1.40 
e191-1 Vehicle 35.2% 30.64 1106.92 6.82 0.218 0.038 1.55 
e191-1 Vehicle 45.2% 33.02 1196.00 6.83 0.236 0.038 1.57 
e191-1 Vehicle 55.0% 32.25 1181.86 6.73 0.217 0.038 1.48 
e191-1 Vehicle 66.0% 32.70 1253.08 6.76 0.220 0.038 1.66 
e191-1 Vehicle 76.1% 32.54 1220.91 6.99 0.219 0.038 2.00 
e191-1 Vehicle 85.3% 31.27 1203.00 7.01 0.220 0.038 2.10 
e191-1 Vehicle 92.6% 30.36 1127.50 7.11 0.220 0.038 1.98 
e191-1 Vehicle 100.0% 29.44 1071.15 7.43 0.219 0.038 2.00 
e191-2 Vehicle 10.0% 30.84 1050.55 6.17 0.201 0.038 1.83 
e191-2 Vehicle 17.6% 31.53 1118.50 6.70 0.196 0.039 1.31 
e191-2 Vehicle 24.1% 30.58 1069.28 6.61 0.205 0.038 1.71 
e191-2 Vehicle 34.0% 29.60 1006.18 6.69 0.207 0.039 1.49 
e191-2 Vehicle 44.4% 31.10 1090.88 6.39 0.205 0.039 1.67 
e191-2 Vehicle 53.9% 32.24 1143.61 6.85 0.201 0.039 1.68 
e191-2 Vehicle 63.1% 31.16 1119.92 6.74 0.207 0.038 1.56 
e191-2 Vehicle 73.7% 31.01 1113.32 6.72 0.207 0.038 1.61 
e191-2 Vehicle 83.9% 32.22 1145.17 6.64 0.208 0.038 2.45 
e191-2 Vehicle 91.7% 30.63 1058.95 6.85 0.207 0.038 1.37 
e191-2 Vehicle 100.0% 30.20 1025.43 6.60 0.206 0.038 1.60 
e191-3 Vehicle 10.0% 28.04 960.08 7.03 0.220 0.038 1.93 
e191-3 Vehicle 21.3% 27.03 868.66 6.92 0.216 0.038 2.22 
e191-3 Vehicle 32.5% 26.05 957.82 7.40 0.220 0.038 2.75 
e191-3 Vehicle 43.8% 25.18 884.89 7.20 0.209 0.039 2.19 
e191-3 Vehicle 55.0% 26.95 888.97 7.64 0.228 0.038 2.61 
e191-3 Vehicle 66.3% 26.38 893.35 7.01 0.218 0.039 2.50 
e191-3 Vehicle 77.5% 26.66 875.49 7.39 0.221 0.038 2.26 
e191-3 Vehicle 88.8% 26.12 868.98 7.88 0.218 0.038 2.45 
e191-3 Vehicle 100.0% 24.86 860.69 7.69 0.216 0.038 2.28 
e191-4 Vehicle 10.0% 27.43 992.47 6.46 0.229 0.038 1.87 
e191-4 Vehicle 21.3% 28.30 997.88 7.01 0.227 0.039 2.21 
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e191-4 Vehicle 32.5% 27.36 912.94 7.29 0.222 0.039 1.63 
e191-4 Vehicle 43.8% 28.43 1050.44 7.49 0.219 0.038 2.73 
e191-4 Vehicle 55.0% 29.19 1082.14 6.84 0.227 0.039 2.52 
e191-4 Vehicle 66.3% 29.50 1056.05 7.37 0.220 0.039 2.46 
e191-4 Vehicle 77.5% 27.81 1061.18 7.10 0.220 0.039 2.45 
e191-4 Vehicle 88.8% 27.19 982.83 7.24 0.212 0.039 1.94 
e191-4 Vehicle 100.0% 28.23 1050.00 7.33 0.213 0.038 1.82 
e191-5 Vehicle 10.0% 28.82 1059.79 6.32 0.213 0.038 1.68 
e191-5 Vehicle 20.0% 30.55 1037.53 7.06 0.215 0.038 1.87 
e191-5 Vehicle 30.0% 31.97 1031.05 6.76 0.216 0.039 1.80 
e191-5 Vehicle 40.0% 30.62 1022.37 6.70 0.225 0.038 1.91 
e191-5 Vehicle 50.0% 32.88 1154.00 6.74 0.225 0.039 1.86 
e191-5 Vehicle 60.0% 30.21 1075.90 6.76 0.219 0.038 2.05 
e191-5 Vehicle 70.0% 29.58 1034.83 6.87 0.218 0.039 3.00 
e191-5 Vehicle 80.0% 29.51 1134.63 6.92 0.212 0.039 2.27 
e191-5 Vehicle 90.0% 28.24 953.28 7.29 0.201 0.039 2.18 
e191-5 Vehicle 100.0% 26.38 1055.35 6.80 0.224 0.039 1.64 
e191-6 Vehicle 10.0% 21.43 754.18 6.23 0.202 0.038 2.06 
e191-6 Vehicle 17.7% 21.87 737.44 6.53 0.201 0.038 1.39 
e191-6 Vehicle 26.2% 39.35 779.77 6.79 0.206 0.038 1.57 
e191-6 Vehicle 35.8% 22.18 755.80 6.71 0.207 0.038 1.50 
e191-6 Vehicle 45.2% 22.47 765.29 7.04 0.205 0.038 1.42 
e191-6 Vehicle 55.7% 22.95 770.69 6.47 0.203 0.038 1.41 
e191-6 Vehicle 66.7% 22.69 786.23 6.65 0.206 0.038 1.40 
e191-6 Vehicle 76.5% 22.82 780.83 6.42 0.204 0.038 1.60 
e191-6 Vehicle 85.5% 21.84 778.31 6.67 0.206 0.038 1.81 
e191-6 Vehicle 92.9% 23.55 835.67 6.71 0.202 0.038 1.62 
e191-6 Vehicle 100.0% 21.84 765.95 6.86 0.209 0.038 1.75 
e191-7 PTH 10.0% 24.14 813.02 7.13 0.216 0.038 2.29 
e191-7 PTH 21.3% 25.54 857.03 7.63 0.214 0.038 2.47 
e191-7 PTH 32.5% 25.29 880.70 7.61 0.213 0.038 2.48 
e191-7 PTH 43.8% 25.41 877.02 7.61 0.209 0.038 3.29 
e191-7 PTH 55.0% 25.15 924.55 7.93 0.212 0.039 2.12 
e191-7 PTH 66.3% 23.52 709.81 7.41 0.218 0.039 1.70 
e191-7 PTH 77.5% 25.05 807.81 7.17 0.210 0.038 2.27 
e191-7 PTH 88.8% 24.82 782.59 8.00 0.212 0.038 2.78 
e191-7 PTH 100.0% 24.40 779.88 7.87 0.219 0.038 2.67 
e191-8 PTH 10.0% 24.60 796.85 6.82 0.208 0.038 2.14 
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e191-8 PTH 21.3% 26.05 866.10 7.49 0.211 0.038 2.40 
e191-8 PTH 32.5% 26.23 864.12 7.49 0.210 0.038 2.12 
e191-8 PTH 43.8% 26.44 856.94 7.32 0.212 0.038 2.59 
e191-8 PTH 55.0% 25.88 837.47 7.40 0.208 0.038 2.03 
e191-8 PTH 66.3% 27.69 874.59 7.53 0.212 0.038 2.30 
e191-8 PTH 77.5% 27.18 905.71 7.33 0.216 0.038 3.01 
e191-8 PTH 88.8% 24.60 857.69 7.33 0.212 0.038 2.58 
e191-8 PTH 100.0% 26.35 891.96 7.64 0.209 0.038 1.89 
e191-9 PTH 10.0% 28.53 939.53 6.99 0.200 0.038 2.69 
e191-9 PTH 20.0% 26.76 891.83 7.47 0.199 0.038 1.54 
e191-9 PTH 30.0% 26.56 844.78 7.38 0.199 0.038 2.53 
e191-9 PTH 40.0% 25.14 845.47 7.66 0.197 0.038 2.43 
e191-9 PTH 50.0% 29.13 928.12 7.58 0.201 0.038 2.78 
e191-9 PTH 60.0% 28.41 919.15 7.69 0.202 0.038 2.88 
e191-9 PTH 70.0% 28.00 873.72 7.38 0.199 0.038 4.30 
e191-9 PTH 80.0% 26.28 882.31 7.69 0.204 0.038 2.70 
e191-9 PTH 90.0% 27.88 944.53 8.28 0.199 0.038 2.25 
e191-9 PTH 100.0% 25.18 809.88 7.63 0.196 0.038 2.56 
e191-10 PTH 10.0% 29.46 914.05 6.86 0.219 0.038 2.31 
e191-10 PTH 21.3% 28.57 863.05 6.95 0.219 0.039 1.81 
e191-10 PTH 32.5% 28.55 878.49 7.15 0.223 0.038 2.75 
e191-10 PTH 43.8% 28.87 917.02 6.75 0.217 0.038 2.24 
e191-10 PTH 55.0% 28.07 915.41 6.63 0.218 0.039 2.08 
e191-10 PTH 66.3% 26.50 892.89 7.15 0.221 0.039 2.15 
e191-10 PTH 77.5% 27.61 920.03 7.12 0.221 0.039 2.36 
e191-10 PTH 88.8% 25.98 822.13 6.93 0.217 0.039 2.25 
e191-10 PTH 100.0% 28.10 893.99 7.41 0.220 0.039 2.30 
e191-11 PTH 10.0% 27.78 939.30 7.26 0.193 0.039 2.45 
e191-11 PTH 20.0% 27.07 841.51 7.47 0.196 0.038 2.36 
e191-11 PTH 30.0% 27.42 894.59 7.67 0.196 0.039 2.37 
e191-11 PTH 40.0% 28.20 926.66 7.95 0.193 0.039 2.35 
e191-11 PTH 50.0% 27.09 905.83 7.59 0.200 0.039 2.65 
e191-11 PTH 60.0% 27.36 975.47 6.73 0.200 0.038 3.33 
e191-11 PTH 70.0% 26.22 930.52 7.98 0.202 0.039 2.42 
e191-11 PTH 80.0% 26.24 873.22 7.62 0.201 0.039 3.02 
e191-11 PTH 90.0% 25.40 861.43 7.22 0.195 0.040 3.17 
e191-11 PTH 100.0% 24.66 824.73 7.95 0.197 0.038 2.63 
e191-12 PTH 10.0% 27.79 1010.03 6.60 0.222 0.038 1.64 
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e191-12 PTH 21.3% 28.54 946.37 6.64 0.218 0.037 1.89 
e191-12 PTH 32.5% 31.18 1261.96 7.03 0.226 0.038 2.14 
e191-12 PTH 43.8% 30.91 1077.77 6.88 0.213 0.038 1.97 
e191-12 PTH 55.0% 30.72 981.97 7.23 0.216 0.039 2.54 
e191-12 PTH 66.3% 33.63 1178.75 6.98 0.209 0.038 1.80 
e191-12 PTH 77.5% 33.60 1137.78 7.19 0.224 0.038 2.21 
e191-12 PTH 88.8% 31.89 1060.56 6.85 0.225 0.038 2.09 
e191-12 PTH 100.0% 32.06 1210.00 7.35 0.222 0.038 2.07 
e191-13 PTH 10.0% 24.67 864.58 6.33 0.200 0.037 2.00 
e191-13 PTH 20.0% 25.32 808.53 7.15 0.204 0.037 1.62 
e191-13 PTH 30.0% 25.39 785.26 7.46 0.210 0.037 1.73 
e191-13 PTH 40.0% 25.62 846.23 7.20 0.209 0.038 1.73 
e191-13 PTH 50.0% 26.38 888.17 7.24 0.218 0.038 2.23 
e191-13 PTH 60.0% 25.67 863.43 6.91 0.217 0.038 1.71 
e191-13 PTH 70.0% 25.03 842.35 7.15 0.212 0.037 2.19 
e191-13 PTH 80.0% 25.82 861.61 7.32 0.214 0.038 2.22 
e191-13 PTH 90.0% 27.37 896.19 7.60 0.210 0.038 2.00 
e191-13 PTH 100.0% 25.72 852.03 7.77 0.206 0.038 3.17 
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Table A.4: Correlations between microstructures, mechanical and material properties 
data used in Chapter 2 
 
Predictor Independent variables r2 p-value 
Mf Crystallinity 0.6 0.002 
logNf Min:Mat 0.27 0.09 
KIc Min:Mat 0.35 0.03 
Crack length Min:Mat 0.29 0.09 
Work to failure Osteon # 0.37 0.04 
Min:Mat Peak height ratio 0.85 <0.0001 
Mf Work to failure 0.22 0.12 
Mf Crack length 0.27 0.1 
Mf KIc 0.32 0.04 
EI KIc 0.56 0.003 
logNf Work to failure 0.31 0.07 
logNf Crack length 0.32 0.07 
Mf Crystallinity + KIc 0.63 0.03 
Mf Crystallinity + Work to failure 0.59 0.008 
Mf Crystallinity + Crack length 0.45 0.04 
logNf Min:Mat + Work to failure 0.32 0.09 
logNf Min:Mat + Crack length 0.42 0.11 
KIc Min:Mat + Mf 0.54 0.008 
KIc Min:Mat + EI 0.67 0.0016 
crack length Min:Mat + Mf + logNf 0.38 0.1 
crack length Min:Mat + Mf 0.39 0.06 
crack length Min:Mat + logNf 0.23 0.14 
crack length Mf + logNf 0.36 0.07 
Work to failure Osteon# + Mf + logNf 0.5 0.05 
Work to failure Osteon# + Mf + logNf + Mf*logNf 0.98 <0.0001 
Work to failure Osteon# + Mf 0.31 0.08 
Work to failure Osteon# + Mf + Osteon#*Mf 0.56 0.022 
Work to failure Osteon# + logNf 0.55 0.02 
Work to failure Osteon# + logNf + Osteon#*logNf 0.82 0.002 
Work to failure Mf + logNf 0.45 0.04 
Work to failure Mf + logNf + Mf*logNf 0.95 <0.0001 
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APPENDIX B: CHAPTER 3 DATA 
 
Table B.1: Microstructural features for cancellous core from distal femurs of sheep 
used in the study in Chapter 3 
 
Sample ID Group BV/TV Conn. D. (#/mm3) Tb.Th (µm) Tb.Sp (mm) 
e191-1 Vehicle 0.293 1.56 231 5.88 
e191-2 Vehicle 0.180 1.12 175 5.61 
e191-3 Vehicle 0.191 1.19 195 4.77 
e191-4 Vehicle 0.352 1.07 240 7.05 
e191-5 Vehicle 0.212 1.03 183 4.31 
e191-6 Vehicle 0.234 0.83 183 9.54 
e191-7 PTH 0.266 1.35 217 3.53 
e191-8 PTH 0.293 1.41 216 4.61 
e191-9 PTH 0.229 1.34 206 3.71 
e191-10 PTH 0.243 1.87 210 3.27 
e191-11 PTH 0.227 1.63 170 7.08 
e191-12 PTH 0.188 1.12 177 3.28 
e191-13 PTH 0.196 1.02 204 4.53 
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Table B.2: Features for plate-like trabeculae in cancellous core of sheep femur used in 
the study in Chapter 3 
 
Sample ID Group 
longitudinal 
Plate/BV 
transverse 
Plate/BV 
oblique 
Plate/BV Plate V/BV 
Plate 
number 
mean 
Plate th. 
(µm) 
e191-1 Vehicle 0.589 0.075 0.214 0.878 3.65 161 
e191-2 Vehicle 0.602 0.069 0.175 0.846 4.05 127 
e191-3 Vehicle 0.704 0.051 0.158 0.913 3.59 165 
e191-4 Vehicle 0.764 0.039 0.144 0.947 3.65 154 
e191-5 Vehicle 0.647 0.065 0.207 0.918 3.57 164 
e191-6 Vehicle 0.692 0.052 0.143 0.888 3.93 133 
e191-7 PTH 0.673 0.057 0.146 0.876 3.83 141 
e191-8 PTH 0.619 0.066 0.201 0.886 3.40 184 
e191-9 PTH 0.530 0.094 0.230 0.854 3.69 156 
e191-10 PTH 0.457 0.079 0.235 0.771 3.51 170 
e191-11 PTH 0.629 0.058 0.159 0.846 4.16 133 
e191-12 PTH 0.630 0.043 0.113 0.786 3.27 185 
e191-13 PTH 0.653 0.056 0.194 0.904 4.75 108 
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Table B.3: Features for rod-like trabeculae in cancellous core of sheep distal femur 
used in the study in Chapter 3 
 
Sample ID Group 
longitudinal 
Rod/BV 
transverse 
Rod/BV 
Oblique 
Rod/BV Rod V/BV 
Rod 
number 
mean Rod 
diameter 
(µm) 
e191-1 Vehicle 0.016 0.060 0.047 0.122 2.59 143 
e191-2 Vehicle 0.011 0.095 0.048 0.154 2.97 130 
e191-3 Vehicle 0.008 0.047 0.033 0.088 2.48 128 
e191-4 Vehicle 0.004 0.034 0.017 0.055 2.31 114 
e191-5 Vehicle 0.007 0.044 0.031 0.082 2.36 136 
e191-6 Vehicle 0.009 0.066 0.038 0.112 2.74 126 
e191-7 PTH 0.019 0.067 0.037 0.124 2.72 129 
e191-8 PTH 0.015 0.055 0.044 0.114 2.46 145 
e191-9 PTH 0.013 0.072 0.061 0.146 2.68 145 
e191-10 PTH 0.036 0.110 0.089 0.235 2.93 152 
e191-11 PTH 0.016 0.084 0.055 0.154 3.09 123 
e191-12 PTH 0.044 0.107 0.064 0.214 2.73 161 
e191-13 PTH 0.010 0.048 0.039 0.096 3.58 76 
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Table B.4: Monotonic mechanical properties for cancellous core of sheep distal femur 
used in the study in Chapter 3 (data except ash fraction were analyzed by Remy Walk) 
 
Sample ID Group 
Young's 
modulus  
(Mpa) 
Yield stress  
(Mpa) 
Ultimate 
stress  
(Mpa) 
Total 
toughness 
to fracture  
(kJ/m3) 
Ash 
fraction (%) 
e191-1 Vehicle 367 3.60 4.74 103 65.2 
e191-2 Vehicle 652 4.08 6.92 145 78.3 
e191-3 Vehicle 425 2.48 3.02 126 72.6 
e191-4 Vehicle 1353 7.86 8.33 50 68.9 
e191-5 Vehicle 1154 6.74 7.17 95 64.2 
e191-6 Vehicle 715 3.84 5.06 124 52.0 
e191-7 PTH 587 4.71 5.70 135 63.2 
e191-8 PTH 386 1.99 3.72 74 86.6 
e191-9 PTH 636 4.00 6.10 83 63.1 
e191-10 PTH 593 3.23 3.50 87 54.2 
e191-11 PTH 1216 6.99 7.90 189 52.3 
e191-12 PTH 1306 7.07 7.72 199 55.8 
e191-13 PTH 947 5.79 6.90 172 55.3 
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Table B.5: Fatigue behavior for cancellous core of sheep distal femur used in the study 
in Chapter 3 
  
Sample ID Group 
Cycles to 
failure 
Initial 
modulus  
(Mpa) 
Modulus loss 
at 50% Nf  
(%) 
Energy 
dissipation 
at 50% Nf  
(kJ/m3) DV/BV 
e191-1 Vehicle 64561 127 NA  NA 
e191-2 Vehicle 106000 323 7.4% 0.169 0.090 
e191-3 Vehicle 15277 546 11.4% 0.258 0.035 
e191-4 Vehicle 260658 710 14.7% 0.334 0.093 
e191-5 Vehicle 3598702 573 25.2% 0.286 0.178 
e191-6 Vehicle 796318 582 16.6% 0.349 0.041 
e191-7 PTH 198800 568 2.6% 0.277 0.076 
e191-8 PTH 424908 481 6.3% 0.251 0.073 
e191-9 PTH 6844999 335 17.1% 0.203 0.218 
e191-10 PTH 81 103 NA NA NA 
e191-11 PTH 80107 555 5.4% 0.280 0.047 
e191-12 PTH 5459 460 7.9% 0.223 0.057 
e191-13 PTH 3052800 698 3.4% 0.165 0.087 
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Table B.6: Nanomechanics and tissue composition for cancellous core of sheep distal 
femur used in the study in Chapter 3  
 
Sample ID Group Zone Er (Gpa) H (Mpa) Min:Mat Crystallinity 
e191-1 Vehicle Superficial 23.7 799 6.25 0.0386 
e191-1 Vehicle Intermediate 23.2 834 6.99 0.0386 
e191-1 Vehicle Central 22.0 730 7.46 0.0384 
e191-2 Vehicle Superficial 20.1 817 5.93 0.0397 
e191-2 Vehicle Intermediate 20.1 766 7.05 0.0392 
e191-2 Vehicle Central 21.5 852 7.59 0.0388 
e191-3 Vehicle Superficial 20.0 939 6.77 0.0392 
e191-3 Vehicle Intermediate 19.8 969 7.20 0.0388 
e191-3 Vehicle Central 19.6 948 8.02 0.0388 
e191-4 Vehicle Superficial 23.5 523 5.68 0.0367 
e191-4 Vehicle Intermediate 28.4 587 6.99 0.0370 
e191-4 Vehicle Central 29.9 642 7.36 0.0375 
e191-5 Vehicle Superficial 21.9 804 6.91 0.0385 
e191-5 Vehicle Intermediate 22.0 798 6.72 0.0389 
e191-5 Vehicle Central 21.4 744 6.91 0.0388 
e191-6 Vehicle Superficial 19.2 749 6.71 0.0388 
e191-6 Vehicle Intermediate 19.9 814 7.33 0.0383 
e191-6 Vehicle Central 20.3 866 8.04 0.0382 
e191-7 PTH Superficial 25.3 980 5.88 0.0390 
e191-7 PTH Intermediate 23.2 853 5.24 0.0390 
e191-7 PTH Central 22.0 790 5.83 0.0388 
e191-8 PTH Superficial 24.6 954 6.26 0.0392 
e191-8 PTH Intermediate 26.7 1049 6.59 0.0390 
e191-8 PTH Central 25.4 967 6.96 0.0390 
e191-9 PTH Superficial 21.3 584 5.99 0.0372 
e191-9 PTH Intermediate 24.0 714 6.19 0.0375 
e191-9 PTH Central 25.1 752 5.42 0.0371 
e191-10 PTH Superficial 21.2 732 5.87 0.0397 
e191-10 PTH Intermediate 28.6 965 6.07 0.0393 
e191-10 PTH Central 27.7 1044 5.69 0.0384 
e191-11 PTH Superficial 25.4 740 6.12 0.0402 
e191-11 PTH Intermediate 24.0 703 6.72 0.0394 
e191-11 PTH Central 25.4 794 7.11 0.0393 
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e191-12 PTH Superficial 21.0 780 6.71 0.0384 
e191-12 PTH Intermediate 21.6 841 6.88 0.0386 
e191-12 PTH Central 20.7 811 7.02 0.0387 
e191-13 PTH Superficial 21.1 810 5.13 0.0397 
e191-13 PTH Intermediate 20.1 737 5.48 0.0394 
e191-13 PTH Central 21.4 770 5.91 0.0391 
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Table B.7: Correlations between microstructures, mechanical and material properties 
for cancellous core of sheep distal femur used in the study in Chapter 3  
 
Predictor Response (Independent Variables) r2 p-value 
Energy Dissipation Rod-type volume fraction 0.4 0.02* 
Energy Dissipation Rod-type Trab. Number 0.24 0.07** 
Energy Dissipation BV/TV 0.37 0.03* 
Energy Dissipation Oblique Rod volume 0.43 0.02* 
Energy Dissipation Min:Mat (superficial) 0.14 0.14 
Energy Dissipation Rod V, Rod N 0.5 0.03* 
Energy Dissipation Ash fraction, BV/TV 0.54 0.02* 
Energy Dissipation Rod V, Rod N, Min:Mat (sup.) 0.74 0.005* 
Energy Dissipation Rod V, Rod N, Min:Mat (centeral) 0.48 0.06** 
Energy Dissipation Rod V, Rod N, Min:Mat (inter.) 0.47 0.06** 
Energy Dissipation Rod V, Rod N, Min:Mat 0.66 0.05* 
Modulus Reduction Rod-type volume fraction 0.03 0.27 
Modulus Reduction Rod-type Trab. Number 0.27 0.06** 
Modulus Reduction Rod N, Min:Mat (sup.) 0.24 0.13 
Modulus Reduction Rod N, Crystallinity (sup.) 0.27 0.12 
Modulus Reduction Rod V, Rod N 0.22 0.15 
Modulus Reduction Ash fraction, BV/TV 0.19 0.17 
Fatigue Life Transverse Plate volume 0.5 0.009* 
Fatigue Life Oblique Plate volume 0.57 0.005* 
Fatigue Life Trans. & Obli. Plate volume 0.55 0.02* 
Initial Modulus Plate-type Trab. volume 0.36 0.03* 
Initial Modulus Longitudinal Plate volume 0.6 0.003* 
Total Toughness Plate thickness 0.26 0.06** 
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APPENDIX C: CHAPTER 4 DATA 
 
Table C.1: Normalized critical load for altered anisotropic fracture toughness (KIy = 
2,4,6,8 MPa√m) of cortical beam under 3-point bending in Chapter 4 (shaded rows 
represented osteon location)  
 
 Normalized critical load 
Crack tip location (mm) KIy = 2 KIy = 4 KIy = 6 KIy = 8 
-0.95 0.000 0.000 0.003 0.000 
-0.9 0.000 0.000 0.002 0.000 
-0.8 0.039 0.062 0.054 0.041 
-0.7 0.003 0.027 0.105 0.178 
-0.6 0.002 0.012 0.035 0.128 
-0.5 0.054 0.034 0.001 0.034 
-0.4 0.004 0.004 0.001 0.003 
-0.3 0.005 0.005 0.000 0.002 
-0.2 0.000 0.000 0.000 0.003 
-0.1 0.000 0.000 0.000 0.001 
0 0.001 0.000 0.000 0.000 
0.1 0.001 0.001 0.000 0.001 
0.2 0.001 0.000 0.000 0.001 
0.3 0.000 0.000 0.000 0.000 
0.4 0.000 0.000 0.000 0.000 
0.5 0.000 0.000 0.000 0.000 
0.6 0.000 0.000 0.000 0.000 
0.7 0.000 0.000 0.000 0.000 
0.8 0.000 0.000 0.000 0.000 
0.9 0.000 0.000 0.000 0.000 
 
  
  146 
Table C.2: Normalized critical load for altered osteon locations of cortical beam under 
3-point bending in Chapter 4 (shaded rows represented osteon location)  
 
 Normalized critical load 
Crack tip location (mm) Location 1 Location 2 Location 3 Location 4 Location 5 
-0.95 0.003 0.001 0.007 0.006 0.006 
-0.9 0.002 0.002 0.013 0.017 0.016 
-0.8 0.054 0.001 0.004 0.008 0.008 
-0.7 0.105 0.002 0.002 0.002 0.001 
-0.6 0.035 0.000 0.002 0.000 0.001 
-0.5 0.001 0.002 0.000 0.001 0.001 
-0.4 0.001 0.077 0.001 0.003 0.000 
-0.3 0.000 0.224 0.002 0.002 0.001 
-0.2 0.000 0.021 0.002 0.000 0.000 
-0.1 0.000 0.003 0.001 0.000 0.000 
0 0.000 0.002 0.054 0.000 0.001 
0.1 0.000 0.001 0.133 0.000 0.000 
0.2 0.000 0.000 0.006 0.000 0.000 
0.3 0.000 0.000 0.002 0.000 0.000 
0.4 0.000 0.000 0.002 0.013 0.001 
0.5 0.000 0.000 0.001 0.074 0.000 
0.6 0.000 0.000 0.000 0.001 0.000 
0.7 0.000 0.000 0.000 0.000 0.000 
0.8 0.000 0.000 0.000 0.000 0.004 
0.9 0.000 0.000 0.000 0.000 0.002 
 
  
  147 
Table C.3: Normalized critical load for altered numbers of osteons (n = 1-5 osteons) of 
cortical beam under 3-point bending in Chapter 4 (shaded rows represented osteon 
location)   
 
 Normalized critical load 
Crack tip location (mm) 1 Osteon 2 Osteon 3 Osteon 4 Osteon 5 Osteon 
-0.95 0.003 0.001 0.000 0.000 0.000 
-0.9 0.002 0.002 0.000 0.000 0.000 
-0.8 0.054 0.026 0.049 0.036 0.069 
-0.7 0.105 0.089 0.099 0.093 0.141 
-0.6 0.035 0.042 0.057 0.038 0.051 
-0.5 0.001 0.011 0.010 0.009 0.007 
-0.4 0.001 0.014 0.031 0.039 0.027 
-0.3 0.000 0.095 0.007 0.129 0.076 
-0.2 0.000 0.021 0.017 0.016 0.033 
-0.1 0.000 0.003 0.002 0.001 0.002 
0 0.000 0.001 0.024 0.026 0.028 
0.1 0.000 0.002 0.040 0.087 0.053 
0.2 0.000 0.001 0.017 0.023 0.018 
0.3 0.000 0.000 0.002 0.001 0.003 
0.4 0.000 0.001 0.000 0.009 0.007 
0.5 0.000 0.000 0.000 0.029 0.024 
0.6 0.000 0.000 0.000 0.005 0.007 
0.7 0.000 0.000 0.000 0.001 0.001 
0.8 0.000 0.000 0.000 0.000 0.003 
0.9 0.000 0.002 0.000 0.000 0.003 
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Table C.4: Normalized critical load for altered osteon thickness (t = 0.2-1 mm) of 
cortical beam under 3-point bending in Chapter 4 (shaded rows represented osteon 
location)    
 
 Normalized critical load 
Crack tip location (mm) 0.2 mm 0.4 mm 0.6 mm 0.8 mm 1.0 mm 
-0.95 0.003 0.002 0.002 0.000 0.000 
-0.9 0.002 0.001 0.001 0.000 0.000 
-0.8 0.054 0.034 0.040 0.038 0.047 
-0.7 0.105 0.058 0.011 0.067 0.099 
-0.6 0.035 0.130 0.014 0.131 0.174 
-0.5 0.001 0.181 0.036 0.247 0.300 
-0.4 0.001 0.040 0.098 0.263 0.281 
-0.3 0.000 0.002 0.182 0.263 0.277 
-0.2 0.000 0.000 0.026 0.280 0.247 
-0.1 0.000 0.000 0.001 0.048 0.249 
0 0.000 0.000 0.000 0.022 0.177 
0.1 0.000 0.000 0.000 0.000 0.210 
0.2 0.000 0.000 0.000 0.001 0.013 
0.3 0.000 0.001 0.000 0.001 0.001 
0.4 0.000 0.000 0.000 0.000 0.000 
0.5 0.000 0.000 0.000 0.000 0.000 
0.6 0.000 0.000 0.000 0.000 0.000 
0.7 0.000 0.000 0.000 0.000 0.000 
0.8 0.000 0.000 0.000 0.000 0.000 
0.9 0.000 0.000 0.000 0.000 0.000 
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APPENDIX D: MATLAB CODE 
 
 
D.1   Fracture Toughness Analysis 
 
Matlab m-file for analyzing fracture toughness load-displacement data in the form of 
text files.  
 
%Fracture Toughness calculation output 
clc; 
clear all; 
close all; 
  
%input data 
prompt = {'input the file name', 'a=', 'W=', 'B=', 'S='};  
dlg_title = 'input'; 
num_lines = 1; 
input = inputdlg(prompt, dlg_title, num_lines); 
str = input{1}; 
a = str2num(input{2})*10^(-3); 
W = str2num(input{3})*10^(-3); 
B = str2num(input{4})*10^(-3); 
S = str2num(input{5})*10^(-3); %unit: mm 
  
[ndata, text, alldata] = xlsread(str); 
lengdata = length(ndata); 
  
clear var text alldata 
  
%offset 
dis_ori = -1*ndata(19:end,4);   %mm 
load_ori = -1*ndata(19:end,5);  %N 
offsetdis = dis_ori(1); 
offsetload = load_ori(1); 
dis = dis_ori - offsetdis; 
load = load_ori - offsetload; 
moment = load*20/2; %N-mm 
  
%plot load-disp plot 
plot(dis, load,'linewidth', 2) 
% title (str) 
xlabel('displacement (mm)') 
ylabel('force (N)') 
  
%max values 
[FORCEmax,index_max] = max(load); %max force 
Dmax = dis(index_max);% displacement at fail (mm) 
MOMENTmax = FORCEmax*20/2; %max moment (N-mm) 
  
%calculate Kc 
R = a/W; 
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Y = 3* (R^0.5) * (1.99-R*(1-R)*(2.15-3.93*R+2.7*R^2)) / 
(2*(1+2*R)*((1-R)^(3/2)));  %ASTM 
kic = FORCEmax*S*Y/B/(W^3/2)  %ASTM 
 
pause 
a=a*10^3;   %um 
W=W*10^3;   %mm 
kic=kic*10^-6;    %M N/m^3/2 
  
%wrtie data to excel sheet 
sfile=fopen(['output_FractureToughness_3076.xls'],'a'); 
fprintf(sfile,'%s,', date); % today's date 
fprintf(sfile,'%s,',str);  %reading name (filename) 
fprintf(sfile,'%.3f,',a);  %notch depth 
fprintf(sfile,'%.3f,',W);  %width 
fprintf(sfile,'%.3f,',FORCEmax); %maximum force 
fprintf(sfile,'%.3f,',kic); %fracture toughness 
fprintf(sfile,'\n'); 
fclose(sfile); 
 
 
D.2   Fatigue Properties Analysis 
 
Matlab m-files for analyzing fatigue testing load-displacement data in the form of text 
files. 
 
%% cancellous fatigue data analysis 
% convert Bose file to strain and stress matrix 
  
% clc;  
clear all;  close all; 
  
prompt = 'Enter the file name:  '; 
str = input(prompt, 's') 
  
leng = 22.19   %eff length 
area = 43.98   %area 
[load, disp] = imtxt(str); 
[nload, ndisp] = trunc(load, disp); 
  
%% calculate/plot stress & strain 
stress = nload(20:end-13)./area; 
strain = ndisp(20:end-13)./leng; 
  
% figure 
% scatter(strain, stress) 
% figure 
% plot(strain, stress) 
  
%% find each minimum strain --> cycle counts and E calculation 
[E,cyc,minstra, indmin, indmax, indmax2] = calE(stress, strain); 
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figure 
plot(strain(indmax(1):indmax2(1)), stress(indmax(1):indmax2(1))) 
hold on 
plot(strain(indmax(2):indmax2(2)), stress(indmax(2):indmax2(2))) 
plot(strain(indmax(3):indmax2(3)), stress(indmax(3):indmax2(3))) 
plot(strain(indmax(100):indmax2(100)), 
stress(indmax(100):indmax2(100))) 
% hold on 
plot(strain(indmax(end):indmax2(end)), 
stress(indmax(end):indmax2(end))) 
hold off 
  
% figure 
% plot(minstra) 
% hold on 
% plot(cyc-1:cyc+4, strain(end-20:end-15)) 
% axis([1, cyc, -1*10^-3,0]) 
figure 
plot(E) 
E(1) 
% axis([1, cyc-1, 0,350]) 
  
j = 1; 
for i = 1:10:length(E) 
    newE(j) = E(i); 
    j = j+1; 
end 
figure 
plot(newE) 
 
%% import text file 
function [load, disp] = imtxt(str) 
    fileID = fopen(str); 
    data = textscan(fileID, '%s %s %n %n %n %n %n'); 
    fclose(fileID); 
    disp = data{4}; 
    load = data{5}; 
end 
 
%% truncate load & disp 
  
function [nnload, nndisp] = trunc(load, disp) 
    load = load - load(2); 
    disp = disp - disp(2); 
     
    Q = fix(length(load)/29); 
    R = rem(length(load),29); 
  
    if R ~= 0 
        newload = zeros(28,Q+1); 
        newdisp = zeros(28,Q+1); 
    else 
        newload = zeros(28, Q); 
        newdisp = zeros(28, Q); 
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    end 
  
    j = 1; 
    for i = 1:length(load) 
            i = i+28*(i-1); 
            newload(1:28, j) = load(i+1:i+28,1); 
            newdisp(1:28, j) = disp(i+1:i+28,1); 
            j = j+1; 
  
            if i+57 > length(load) 
                i = i+29; 
                newload(1:R-1, j) = load(i+1:end); 
                newdisp(1:R-1, j) = disp(i+1:end); 
                break 
            end       
    end 
  
    j = 1; 
    for i = 1:Q 
        i = 27*(i-1)+i; 
        nnload(i:i+27,1) = newload(1:28, j); 
        nndisp(i:i+27,1) = newdisp(1:28, j); 
        j = j+1; 
    end 
  
    if R ~= 0 
        nnload(28*Q+1:28*Q+R-1, 1) = newload(1:R-1, Q+1); 
        nndisp(28*Q+1:28*Q+R-1, 1) = newdisp(1:R-1, Q+1); 
    end 
end 
 
%% calculate E & cycle 
  
function [E, cyc, minstra, indmin, indmax, indmax2] = calE(stress, 
strain) 
i = 1; cyc = 1; 
   while 1 
       [cycL] = [i:i+6]; 
       maxL = find(strain(cycL)==max(strain(cycL)));   %start of 
loading portion 
       [indxx] = [maxL(1)+ i-1]; 
  
       [cycL] = [indxx(1)+1 : indxx(1)+6]; 
       min2L = find(strain(cycL)==min(strain(cycL)));   %local 
index in strain 
       [indxn2] = [min2L(1)+ indxx(1)];    %global index in strain 
  
       [cycL] = [indxn2(1)+1 : indxn2(1)+6]; 
       max2L = find(strain(cycL)==max(strain(cycL))); 
       [indxx2] = [max2L(1)+ indxn2(1)]; 
%         
%        figure 
%        plot(strain(indxx(1):indxx2(1)), 
stress(indxx(1):indxx2(1))) 
%        axis([-2.5*10^-2,0, -1.8,0]); 
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%        pause 
        
       [pf] = polyfit(strain(indxx(1):indxx2(1)), 
stress(indxx(1):indxx2(1)), 2); 
%        E(cyc) = 2*pf(1)*strain( floor((cyc + indx(1))/2) ) + 
pf(2) 
%        E(cyc+1) = 2*pf(1)*strain( floor((indx(1) + indx2(1))/2) ) 
+ pf(2) 
       E(cyc) = 2*pf(1)*strain(indxn2(1)) + pf(2); 
  
       minstra(cyc) = strain(indxn2(1)); 
       indmin(cyc) = indxn2(1); 
       indmax(cyc) = indxx(1); 
       indmax2(cyc) = indxx2(1); 
       cyc = cyc+1; 
       
       i = indxx2(1)+1; 
       if i > length(strain)-20 
           return 
       end 
  
   end 
end 
 
 
 
 
 
